risperidone has been researched along with Cognition Disorders in 165 studies
Risperidone: A selective blocker of DOPAMINE D2 RECEPTORS and SEROTONIN 5-HT2 RECEPTORS that acts as an atypical antipsychotic agent. It has been shown to improve both positive and negative symptoms in the treatment of SCHIZOPHRENIA.
risperidone : A member of the class of pyridopyrimidines that is 2-methyl-6,7,8,9-tetrahydropyrido[1,2-a]pyrimidin-4-one carrying an additional 2-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]ethyl group at position 2.
Cognition Disorders: Disorders characterized by disturbances in mental processes related to learning, thinking, reasoning, and judgment.
| Excerpt | Relevance | Reference |
|---|---|---|
| "This study was to evaluate the effects on clinical symptoms and cognitive function of switching the treatment of elderly patients with schizophrenia from risperidone to paliperidone (PAL)." | 9.19 | The influence of switching from risperidone to paliperidone on the extrapyramidal symptoms and cognitive function in elderly patients with schizophrenia: a preliminary open-label trial. ( Gen, K; Hibino, H; Inoue, Y; Matsumoto, H; Mikami, A; Mikami, K; Suzuki, H, 2014) |
| "Ninety-two patients with early stage schizophrenia treated with risperidone entered this 16-week, double blind, randomized, placebo-controlled clinical trial." | 9.19 | Minocycline supplementation for treatment of negative symptoms in early-phase schizophrenia: a double blind, randomized, controlled trial. ( Guo, X; Liu, F; Ou, J; Ruan, Y; Wu, R; Xie, L; Xu, X; Yang, J; Yang, L; Yang, S; Zeng, Y; Zhang, B; Zhang, L; Zhao, J; Zheng, Y, 2014) |
| "Clozapine, the most widely used option in treatment-resistant schizophrenia, has been shown to be superior to other antipsychotic medications in improving cognitive function in patients." | 9.17 | Clozapine and visuospatial processing in treatment-resistant schizophrenia. ( Bourque, J; Champagne, J; Lakis, N; Lalonde, P; Lipp, O; Mendrek, A; Stip, E, 2013) |
| " Aripiprazole, which is a partial dopamine D2 receptor agonist, may have an impact on cognitive dysfunction in patients with schizophrenia." | 9.16 | Effect of adjunctive treatment with aripiprazole to atypical antipsychotics on cognitive function in schizophrenia patients. ( Kaneda, A; Kaneko, S; Sugawara, N; Tomita, T; Yasui-Furukori, N, 2012) |
| "This study aims to determine the effectiveness of paliperidone extended release (ER) on cognitive function in patients with schizophrenia in comparison with risperidone." | 9.16 | Paliperidone ER versus risperidone for neurocognitive function in patients with schizophrenia: a randomized, open-label, controlled trial. ( Bae, KY; Chung, YC; Kim, JM; Kim, SW; Kim, SY; Lee, JH; Lee, YH; Shin, IS; Yoon, JS, 2012) |
| "Evaluation of risperidone efficacy at psychopathological symptoms, cognitive impairment and formal thought disorder in adolescents with schizophrenia spectrum diagnosis." | 9.16 | Cognition and communication dysfunctions in early-onset schizophrenia: effect of risperidone. ( Namysłowska, I; Remberk, B; Rybakowski, F, 2012) |
| "This study was a comparative investigation of the effects on clinical symptoms and cognitive function of switching the treatment of schizophrenia patients from haloperidol decanoate depot to risperidone long-acting injection (RLAI) compared with a control group that continued receiving haloperidol decanoate depot." | 9.16 | The influence of switching from haloperidol decanoate depot to risperidone long-acting injection on the clinical symptoms and cognitive function in schizophrenia. ( Gen, K; Suzuki, H, 2012) |
| "Galantamine, a reversible cholinesterase inhibitor with effects on nicotinic receptors, has shown mixed effects on cognitive impairments in patients with schizophrenia." | 9.15 | Galantamine augmentation of long-acting injectable risperidone for cognitive impairments in chronic schizophrenia. ( Khan, A; Lindenmayer, JP, 2011) |
| "This preliminary study aimed to determine if adding mirtazapine to risperidone might improve negative and cognitive symptoms in schizophrenia." | 9.15 | Mirtazapine augmentation enhances cognitive and reduces negative symptoms in schizophrenia patients treated with risperidone: a randomized controlled trial. ( Cho, SJ; Choi, TK; Kim, B; Kim, YW; Lee, JE; Lee, KS; Lee, SH; Suh, S; Yook, K; Yook, KH, 2011) |
| "Risperidone treatment can improve disgust recognition deficits in patients with schizophrenia." | 9.14 | Effect of risperidone on emotion recognition deficits in antipsychotic-naïve schizophrenia: a short-term follow-up study. ( Arasappa, R; Behere, RV; Gangadhar, BN; Reddy, N; Venkatasubramanian, G, 2009) |
| "To investigate changes in cognitive function and clinical features following a switch from oral atypical antipsychotics (AAPs) to long-acting injectable risperidone (LAIR) in patients with schizophrenia." | 9.14 | Effects of switching to long-acting injectable risperidone from oral atypical antipsychotics on cognitive function in patients with schizophrenia. ( Kim, JM; Kim, SW; Lee, SH; Lee, YH; Shin, IS; Yang, SJ; Yoon, JS, 2009) |
| "To evaluate the efficacy and tolerability of armodafinil, the longer-lasting isomer of modafinil, as adjunctive therapy in patients with schizophrenia." | 9.14 | Armodafinil as adjunctive therapy in adults with cognitive deficits associated with schizophrenia: a 4-week, double-blind, placebo-controlled study. ( D'Souza, DC; Kane, JM; Keefe, RS; Patkar, AA; Tiller, JM; Yang, R; Youakim, JM, 2010) |
| "The objective of this research was to explore the effects of risperidone on cognitive processes in children with autism and irritable behavior." | 9.13 | Cognitive effects of risperidone in children with autism and irritable behavior. ( Aman, MG; Arnold, LE; Cronin, P; Gavaletz, A; Ghuman, JK; Hollway, JA; Koenig, K; McCracken, JT; McDougle, CJ; Posey, DJ; Ritz, L; Scahill, L; Swiezy, N; Tierney, E; Vitiello, B; Wheeler, C, 2008) |
| "To compare the efficacy and tolerability of quetiapine and risperidone in the treatment of schizophrenia." | 9.12 | Comparison of quetiapine and risperidone in the treatment of schizophrenia: A randomized, double-blind, flexible-dose, 8-week study. ( Hamer, RM; Lieberman, JA; Sweitzer, DE; Zhong, KX, 2006) |
| "Adjunctive treatment with risperidone for 6 weeks in patients with schizophrenia who had received chronic treatment with clozapine does not significantly improve cognitive function." | 9.12 | A double-blind study of combination of clozapine with risperidone in patients with schizophrenia: effects on cognition. ( Akdede, BB; Alptekin, K; Anil Yağcioğlu, AE; Göğüş, A; Jayathilake, K; Meltzer, HY; Tümüklü, M; Tunca, Z; Turgut, TI; Yazici, MK, 2006) |
| "To compare olanzapine and risperidone outcome on some neurocognitive dimensions in chronic schizophrenia patients with prominent negative symptoms." | 9.12 | Effect of olanzapine or risperidone treatment on some cognitive functions in a one-year follow-up of schizophrenia outpatients with prominent negative symptoms. ( Alvarez, E; Bousoño, M; Carlos Gómez, J; Ciudad, A; Gurpegui, M; Olivares, JM, 2007) |
| "This post hoc analysis explored the role of insight as a mediator of functioning in a 52-week, double-blind, international trial of 323 patients with schizophrenia or schizoaffective disorder receiving risperidone long-acting injectable." | 9.12 | The impact of insight on functioning in patients with schizophrenia or schizoaffective disorder receiving risperidone long-acting injectable. ( Bossie, C; Gharabawi, G; Kujawa, M; Mahmoud, R; Simpson, G; Turkoz, I, 2007) |
| "The aim of this study was to evaluate the efficacy and safety of risperidone in the treatment of patients with delirium." | 9.11 | Risperidone in the treatment of patients with delirium. ( Baeza, I; de Pablo, J; Martínez, G; Parellada, E, 2004) |
| "Eighty-six patients with probable Alzheimer's disease, vascular dementia, or mixed-etiology dementia (DSM-IV criteria) were randomly assigned to treatment with olanzapine or risperidone." | 9.11 | Correlates of anticholinergic activity in patients with dementia and psychosis treated with risperidone or olanzapine. ( Bastean, JN; Bossie, CA; Gharabawi, GM; Greenspan, AJ; Mao, L; Martinez, RA; Mulsant, BH; Pollock, BG; Tune, LE, 2004) |
| "To examine the effects of risperidone and olanzapine on cognitive functioning in elderly patients with schizophrenia or schizoaffective disorder." | 9.10 | Comparative effects of risperidone and olanzapine on cognition in elderly patients with schizophrenia or schizoaffective disorder. ( Gharabawi, G; Harvey, PD; Mao, L; Napolitano, JA, 2003) |
| "The subjects were 20 outpatients with schizophrenia or schizoaffective disorder who were clinically stable on a regimen of clozapine at the time of screening." | 9.08 | Different side effect profiles of risperidone and clozapine in 20 outpatients with schizophrenia or schizoaffective disorder: a pilot study. ( Daniel, DG; Goldberg, TE; Kleinman, JE; Lubick, LJ; Pickar, D; Weinberger, DR; Williams, TS, 1996) |
| "The aim of this review was to discuss data from double-blind, randomized controlled trials (RCTs) that have investigated the effects of oral and long-acting injectable risperidone on cognitive and psychomotor functioning in patients with schizophrenia or schizoaffective disorder." | 8.84 | Cognitive and psychomotor effects of risperidone in schizophrenia and schizoaffective disorder. ( Houthoofd, SA; Morrens, M; Sabbe, BG, 2008) |
| "Olanzapine demonstrated superior antipsychotic efficacy compared with haloperidol in the treatment of acute phase schizophrenia, and in the treatment of some patients with first-episode or treatment-resistant schizophrenia." | 8.81 | Olanzapine: an updated review of its use in the management of schizophrenia. ( Bhana, N; Foster, RH; Olney, R; Plosker, GL, 2001) |
| "Risperidone offers physicians the unique combination of extensive, published clinical experience and a good safety profile for treating patients with dementia who have symptoms of aggression, agitation, and psychosis." | 8.81 | Risperidone for the treatment of behavioral and psychological symptoms of dementia. ( Tune, LE, 2001) |
| "After a switch from previous treatment to open-label ziprasidone more than half of patients with schizophrenia experienced sustained clinical remission over 6 months and 32% of the patients achieving remission experienced a concurrent NP improvement." | 7.74 | The relationship between symptomatic remission and neuropsychological improvement in schizophrenia patients switched to treatment with ziprasidone. ( Bowie, CR; Buckley, PF; Harvey, PD; Loebel, A, 2007) |
| "Our results support the previously reported positive impact of atypical antipsychotics, particularly olanzapine, in patients with schizophrenia." | 7.72 | Effectiveness of antipsychotic treatments for schizophrenia: interim 6-month analysis from a prospective observational study (IC-SOHO) comparing olanzapine, quetiapine, risperidone, and haloperidol. ( Bitter, I; Boland, J; Dossenbach, M; el Mahfoud Kessaci, M; Erol, A; Hodge, A; O'Halloran, RA; Shaheen, MO; Sunbol, MM, 2004) |
| "Guanfacine has demonstrated efficacy in reversing working memory deficits in non-human primate." | 6.70 | Guanfacine treatment of cognitive impairment in schizophrenia. ( Adler, DN; Davis, KL; Friedman, JI; Harvey, PD; Kemether, E; Parrella, M; Temporini, HD; White, L, 2001) |
| "Treatment on risperidone also resulted in significant reduction in the PANSS score." | 6.70 | The effect of risperidone on cognitive functioning in a sample of Asian patients with schizophrenia in Singapore. ( Chan, YH; Chong, SA; Chua, L; Ng, VP; Pang, E, 2001) |
| "Risperidone-treated subjects with a greater degree of acute mood change were both 3." | 6.69 | The course of depressive symptoms in predicting relapse in schizophrenia: a double-blind, randomized comparison of olanzapine and risperidone. ( Andersen, SW; Tollefson, GD; Tran, PV, 1999) |
| "Cariprazine is a dopamine D3/D2 receptor partial agonist with preferential binding to D3 receptors, recently approved by the FDA for the treatment of schizophrenia and manic or mixed episodes associated with bipolar I disorder." | 5.43 | Effects of cariprazine, a novel antipsychotic, on cognitive deficit and negative symptoms in a rodent model of schizophrenia symptomatology. ( Adham, N; Ferguson, P; Grayson, B; Gyertyán, I; Kiss, B; Neill, JC, 2016) |
| "This study was to evaluate the effects on clinical symptoms and cognitive function of switching the treatment of elderly patients with schizophrenia from risperidone to paliperidone (PAL)." | 5.19 | The influence of switching from risperidone to paliperidone on the extrapyramidal symptoms and cognitive function in elderly patients with schizophrenia: a preliminary open-label trial. ( Gen, K; Hibino, H; Inoue, Y; Matsumoto, H; Mikami, A; Mikami, K; Suzuki, H, 2014) |
| "Ninety-two patients with early stage schizophrenia treated with risperidone entered this 16-week, double blind, randomized, placebo-controlled clinical trial." | 5.19 | Minocycline supplementation for treatment of negative symptoms in early-phase schizophrenia: a double blind, randomized, controlled trial. ( Guo, X; Liu, F; Ou, J; Ruan, Y; Wu, R; Xie, L; Xu, X; Yang, J; Yang, L; Yang, S; Zeng, Y; Zhang, B; Zhang, L; Zhao, J; Zheng, Y, 2014) |
| "This was a post hoc analysis of a 52-week, prospective, randomized, double-blind study (N=323) comparing 2 doses of risperidone long-acting injectable (RLAI) in stable subjects with schizophrenia or schizoaffective disorder." | 5.17 | Identification of clinically meaningful relationships among cognition, functionality, and symptoms in subjects with schizophrenia or schizoaffective disorder. ( Alphs, L; Bilder, R; Pandina, G; Turkoz, I, 2013) |
| "Clozapine, the most widely used option in treatment-resistant schizophrenia, has been shown to be superior to other antipsychotic medications in improving cognitive function in patients." | 5.17 | Clozapine and visuospatial processing in treatment-resistant schizophrenia. ( Bourque, J; Champagne, J; Lakis, N; Lalonde, P; Lipp, O; Mendrek, A; Stip, E, 2013) |
| " Aripiprazole, which is a partial dopamine D2 receptor agonist, may have an impact on cognitive dysfunction in patients with schizophrenia." | 5.16 | Effect of adjunctive treatment with aripiprazole to atypical antipsychotics on cognitive function in schizophrenia patients. ( Kaneda, A; Kaneko, S; Sugawara, N; Tomita, T; Yasui-Furukori, N, 2012) |
| "Neurocognitive functioning of youth (ages 8 to 19 years) with schizophrenia or schizoaffective disorder was evaluated in a four-site, randomized, double-blind clinical trial comparing molindone, olanzapine, and risperidone." | 5.16 | Neurocognitive outcomes in the Treatment of Early-Onset Schizophrenia Spectrum Disorders study. ( Breiger, D; Findling, RL; Frazier, JA; Giuliano, AJ; Hamer, RM; Hooper, SR; Johnson, JL; Lieberman, JA; McClellan, J; Sikich, L; Vitiello, B; Yakutis, L; Youngstrom, EA, 2012) |
| "This study aims to determine the effectiveness of paliperidone extended release (ER) on cognitive function in patients with schizophrenia in comparison with risperidone." | 5.16 | Paliperidone ER versus risperidone for neurocognitive function in patients with schizophrenia: a randomized, open-label, controlled trial. ( Bae, KY; Chung, YC; Kim, JM; Kim, SW; Kim, SY; Lee, JH; Lee, YH; Shin, IS; Yoon, JS, 2012) |
| "Evaluation of risperidone efficacy at psychopathological symptoms, cognitive impairment and formal thought disorder in adolescents with schizophrenia spectrum diagnosis." | 5.16 | Cognition and communication dysfunctions in early-onset schizophrenia: effect of risperidone. ( Namysłowska, I; Remberk, B; Rybakowski, F, 2012) |
| "We investigated the effects of risperidone (N=16), olanzapine (N=18) and low doses of haloperidol (N=18) in cortical thickness changes during 1-year follow-up period in a large and heterogeneous sample of schizophrenia spectrum patients." | 5.16 | Effect of antipsychotic drugs on cortical thickness. A randomized controlled one-year follow-up study of haloperidol, risperidone and olanzapine. ( Ayesa-Arriola, R; Crespo-Facorro, B; Gutiérrez, A; Ortíz-García de la Foz, V; Roiz-Santiáñez, R; Tabarés-Seisdedos, R; Tordesillas-Gutiérrez, D; Vázquez-Barquero, JL, 2012) |
| "This study was a comparative investigation of the effects on clinical symptoms and cognitive function of switching the treatment of schizophrenia patients from haloperidol decanoate depot to risperidone long-acting injection (RLAI) compared with a control group that continued receiving haloperidol decanoate depot." | 5.16 | The influence of switching from haloperidol decanoate depot to risperidone long-acting injection on the clinical symptoms and cognitive function in schizophrenia. ( Gen, K; Suzuki, H, 2012) |
| "363 hospital-based psychiatric patients in India, Romania, and United States aged 18 to 65 years and meeting criteria for DSM-IV-TR diagnosis of chronic schizophrenia were randomized double-blind to receive BL-1020 10 mg/d, BL-1020 20-30 mg/d, placebo, or risperidone (2-8 mg/d) for 6 weeks." | 5.16 | Bl-1020, a new γ-aminobutyric acid-enhanced antipsychotic: results of 6-week, randomized, double-blind, controlled, efficacy and safety study. ( Anand, R; Davidson, M; Geffen, Y; Keefe, R; Rabinowitz, J, 2012) |
| "Galantamine, a reversible cholinesterase inhibitor with effects on nicotinic receptors, has shown mixed effects on cognitive impairments in patients with schizophrenia." | 5.15 | Galantamine augmentation of long-acting injectable risperidone for cognitive impairments in chronic schizophrenia. ( Khan, A; Lindenmayer, JP, 2011) |
| "In a clinical trial comparing risperidone and lurasidone, 323 clinically-stable outpatients with schizophrenia at 29 sites were assessed with MCCB at screening and a median of 15days later at baseline." | 5.15 | Characteristics of the MATRICS Consensus Cognitive Battery in a 29-site antipsychotic schizophrenia clinical trial. ( Cucchiaro, J; Fox, KH; Harvey, PD; Keefe, RS; Loebel, A; Siu, C, 2011) |
| "This preliminary study aimed to determine if adding mirtazapine to risperidone might improve negative and cognitive symptoms in schizophrenia." | 5.15 | Mirtazapine augmentation enhances cognitive and reduces negative symptoms in schizophrenia patients treated with risperidone: a randomized controlled trial. ( Cho, SJ; Choi, TK; Kim, B; Kim, YW; Lee, JE; Lee, KS; Lee, SH; Suh, S; Yook, K; Yook, KH, 2011) |
| " One hundred two patients with first episode schizophrenia or schizoaffective disorder were assessed on cognitive measures of speed of processing, episodic memory, executive function, and visual spatial processing at baseline (when patients were drug naive and after 16 weeks of olanzapine or risperidone treatment), so that a change score could be derived." | 5.14 | Lack of an inverse relationship between duration of untreated psychosis and cognitive function in first episode schizophrenia. ( Burdick, KE; Goldberg, TE; Goldman, R; Kane, JM; Lencz, T; Malhotra, AK; McCormack, J; Napolitano, B; Patel, RC; Robinson, DG; Sevy, SM, 2009) |
| "Risperidone treatment can improve disgust recognition deficits in patients with schizophrenia." | 5.14 | Effect of risperidone on emotion recognition deficits in antipsychotic-naïve schizophrenia: a short-term follow-up study. ( Arasappa, R; Behere, RV; Gangadhar, BN; Reddy, N; Venkatasubramanian, G, 2009) |
| "To investigate changes in cognitive function and clinical features following a switch from oral atypical antipsychotics (AAPs) to long-acting injectable risperidone (LAIR) in patients with schizophrenia." | 5.14 | Effects of switching to long-acting injectable risperidone from oral atypical antipsychotics on cognitive function in patients with schizophrenia. ( Kim, JM; Kim, SW; Lee, SH; Lee, YH; Shin, IS; Yang, SJ; Yoon, JS, 2009) |
| "To evaluate the efficacy and tolerability of armodafinil, the longer-lasting isomer of modafinil, as adjunctive therapy in patients with schizophrenia." | 5.14 | Armodafinil as adjunctive therapy in adults with cognitive deficits associated with schizophrenia: a 4-week, double-blind, placebo-controlled study. ( D'Souza, DC; Kane, JM; Keefe, RS; Patkar, AA; Tiller, JM; Yang, R; Youakim, JM, 2010) |
| "The objective of this research was to explore the effects of risperidone on cognitive processes in children with autism and irritable behavior." | 5.13 | Cognitive effects of risperidone in children with autism and irritable behavior. ( Aman, MG; Arnold, LE; Cronin, P; Gavaletz, A; Ghuman, JK; Hollway, JA; Koenig, K; McCracken, JT; McDougle, CJ; Posey, DJ; Ritz, L; Scahill, L; Swiezy, N; Tierney, E; Vitiello, B; Wheeler, C, 2008) |
| "First-episode patients with schizophrenia, schizophreniform disorder, or schizoaffective disorder (DSM-IV) were randomly assigned to olanzapine (2." | 5.13 | Predictors of treatment discontinuation and medication nonadherence in patients recovering from a first episode of schizophrenia, schizophreniform disorder, or schizoaffective disorder: a randomized, double-blind, flexible-dose, multicenter study. ( Gu, H; Hamer, RM; Lieberman, JA; McEvoy, JP; Perkins, DO; Weiden, PJ, 2008) |
| "To compare the efficacy and tolerability of quetiapine and risperidone in the treatment of schizophrenia." | 5.12 | Comparison of quetiapine and risperidone in the treatment of schizophrenia: A randomized, double-blind, flexible-dose, 8-week study. ( Hamer, RM; Lieberman, JA; Sweitzer, DE; Zhong, KX, 2006) |
| "Patients with schizophrenia were randomly assigned in a 1:1 ratio to receive treatment with either quetiapine (dose range: 200-800 mg/day) or risperidone (dose range: 2-8 mg/day) for an 8-week period." | 5.12 | Improvement in social competence with short-term atypical antipsychotic treatment: a randomized, double-blind comparison of quetiapine versus risperidone for social competence, social cognition, and neuropsychological functioning. ( Brecher, M; Harvey, PD; Patterson, TL; Potter, LS; Zhong, K, 2006) |
| "Adjunctive treatment with risperidone for 6 weeks in patients with schizophrenia who had received chronic treatment with clozapine does not significantly improve cognitive function." | 5.12 | A double-blind study of combination of clozapine with risperidone in patients with schizophrenia: effects on cognition. ( Akdede, BB; Alptekin, K; Anil Yağcioğlu, AE; Göğüş, A; Jayathilake, K; Meltzer, HY; Tümüklü, M; Tunca, Z; Turgut, TI; Yazici, MK, 2006) |
| "To compare olanzapine and risperidone outcome on some neurocognitive dimensions in chronic schizophrenia patients with prominent negative symptoms." | 5.12 | Effect of olanzapine or risperidone treatment on some cognitive functions in a one-year follow-up of schizophrenia outpatients with prominent negative symptoms. ( Alvarez, E; Bousoño, M; Carlos Gómez, J; Ciudad, A; Gurpegui, M; Olivares, JM, 2007) |
| "Randomized, double-blind study of patients with schizophrenia assigned to receive treatment with olanzapine, perphenazine, quetiapine fumarate, or risperidone for up to 18 months as reported previously by Lieberman et al." | 5.12 | Neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE Trial. ( Bilder, RM; Capuano, G; Davis, CE; Davis, SM; Gold, JM; Green, MF; Harvey, PD; Hsiao, JK; Keefe, RS; Lieberman, JA; McEvoy, JP; Meltzer, HY; Palmer, BW; Perkins, DO; Rosenheck, RA; Stroup, TS; Swartz, MS, 2007) |
| " The primary objective of this double-blind study was to compare the effects of treatment initiation with risperidone and quetiapine on cognitive function in subjects with stable bipolar disorder." | 5.12 | Cognitive functioning and acute sedative effects of risperidone and quetiapine in patients with stable bipolar I disorder: a randomized, double-blind, crossover study. ( Engelhart, LM; Gharabawi, GM; Harvey, PD; Hassman, H; Mahmoud, RA; Mao, L, 2007) |
| "To report the results on cognition of a randomized comparison of 2 widely prescribed second-generation antipsychotic medications, olanzapine and risperidone, in patients with first-episode schizophrenia and a healthy control group." | 5.12 | Cognitive improvement after treatment with second-generation antipsychotic medications in first-episode schizophrenia: is it a practice effect? ( Burdick, KE; Goldberg, TE; Goldman, RS; Kane, JM; Lencz, T; Malhotra, AK; Patel, RC; Robinson, DG; Schooler, NR; Woerner, MG, 2007) |
| "This post hoc analysis explored the role of insight as a mediator of functioning in a 52-week, double-blind, international trial of 323 patients with schizophrenia or schizoaffective disorder receiving risperidone long-acting injectable." | 5.12 | The impact of insight on functioning in patients with schizophrenia or schizoaffective disorder receiving risperidone long-acting injectable. ( Bossie, C; Gharabawi, G; Kujawa, M; Mahmoud, R; Simpson, G; Turkoz, I, 2007) |
| "The purpose of this investigation was to evaluate the effects of clozapine and risperidone on social skill and problem solving in patients with schizophrenia." | 5.11 | Do clozapine and risperidone affect social competence and problem solving? ( Bellack, AS; Brown, CH; Kane, JM; Marder, SR; Schooler, NR; Yang, Y, 2004) |
| "307 schizophrenia subjects in their first episode of illness were recruited to participate in a clinical trial comparing the long-term efficacy of haloperidol and risperidone." | 5.11 | Correlates of cognitive deficits in first episode schizophrenia. ( Csernansky, JG; DeLisi, LE; Heydebrand, G; Hoff, AL; Rabinowitz, J; Weiser, M, 2004) |
| "The aim of this study was to evaluate the efficacy and safety of risperidone in the treatment of patients with delirium." | 5.11 | Risperidone in the treatment of patients with delirium. ( Baeza, I; de Pablo, J; Martínez, G; Parellada, E, 2004) |
| "Eighty-six patients with probable Alzheimer's disease, vascular dementia, or mixed-etiology dementia (DSM-IV criteria) were randomly assigned to treatment with olanzapine or risperidone." | 5.11 | Correlates of anticholinergic activity in patients with dementia and psychosis treated with risperidone or olanzapine. ( Bastean, JN; Bossie, CA; Gharabawi, GM; Greenspan, AJ; Mao, L; Martinez, RA; Mulsant, BH; Pollock, BG; Tune, LE, 2004) |
| "Cerebral cortical gray was examined volumetrically in 19 patients with schizophrenia before and following 28 days of treatment with two SGAs (risperidone and ziprasidone; n = 13) or a FGA (haloperidol; n = 6)." | 5.11 | Cerebral cortical gray expansion associated with two second-generation antipsychotics. ( Christensen, JD; Garver, DL; Holcomb, JA, 2005) |
| "Cognitive assessments were conducted in 533 patients experiencing their first episode of schizophrenia or a related psychosis who had been randomly assigned to receive low doses of risperidone or haloperidol." | 5.11 | Treatment of cognitive impairment in early psychosis: a comparison of risperidone and haloperidol in a large long-term trial. ( Davidson, M; Eerdekens, M; Harvey, PD; Rabinowitz, J, 2005) |
| "The effects of risperidone and olanzapine on cognitive functioning in patients with schizophrenia were compared in a randomized, double-blind trial." | 5.10 | Changes in cognitive functioning with risperidone and olanzapine treatment: a large-scale, double-blind, randomized study. ( Green, MF; Harvey, PD; McGurk, SR; Meltzer, HY, 2003) |
| "To examine the effects of risperidone and olanzapine on cognitive functioning in elderly patients with schizophrenia or schizoaffective disorder." | 5.10 | Comparative effects of risperidone and olanzapine on cognition in elderly patients with schizophrenia or schizoaffective disorder. ( Gharabawi, G; Harvey, PD; Mao, L; Napolitano, JA, 2003) |
| "The subjects were 20 outpatients with schizophrenia or schizoaffective disorder who were clinically stable on a regimen of clozapine at the time of screening." | 5.08 | Different side effect profiles of risperidone and clozapine in 20 outpatients with schizophrenia or schizoaffective disorder: a pilot study. ( Daniel, DG; Goldberg, TE; Kleinman, JE; Lubick, LJ; Pickar, D; Weinberger, DR; Williams, TS, 1996) |
| "The aim of this review was to discuss data from double-blind, randomized controlled trials (RCTs) that have investigated the effects of oral and long-acting injectable risperidone on cognitive and psychomotor functioning in patients with schizophrenia or schizoaffective disorder." | 4.84 | Cognitive and psychomotor effects of risperidone in schizophrenia and schizoaffective disorder. ( Houthoofd, SA; Morrens, M; Sabbe, BG, 2008) |
| "Olanzapine demonstrated superior antipsychotic efficacy compared with haloperidol in the treatment of acute phase schizophrenia, and in the treatment of some patients with first-episode or treatment-resistant schizophrenia." | 4.81 | Olanzapine: an updated review of its use in the management of schizophrenia. ( Bhana, N; Foster, RH; Olney, R; Plosker, GL, 2001) |
| "Risperidone offers physicians the unique combination of extensive, published clinical experience and a good safety profile for treating patients with dementia who have symptoms of aggression, agitation, and psychosis." | 4.81 | Risperidone for the treatment of behavioral and psychological symptoms of dementia. ( Tune, LE, 2001) |
| "Clozapine has proved effective in alleviating a wide range of psychiatric symptoms in schizophrenia." | 4.79 | The effects of clozapine on neurocognition: an overview. ( Goldberg, TE; Weinberger, DR, 1994) |
| "The present study thus indicates that the interacting effects within the COMT gene polymorphisms may influence the disease status and response to risperidone in schizophrenia patients." | 3.75 | Association studies of catechol-O-methyltransferase (COMT) gene with schizophrenia and response to antipsychotic treatment. ( Baghel, R; Bhasin, Y; Bhatnagar, P; Brahmachari, SK; Chauhan, C; Grover, S; Gupta, M; Jain, S; Kaur, H; Kukreti, R; Manduva, V; Mukherjee, O; Purushottam, M; Sharma, A; Verma, B, 2009) |
| "Disruptions in 5-CSRTT performance induced by repeated PCP administration are prevented by chronic clozapine treatment and may constitute a useful animal model of some cognitive symptoms of schizophrenia." | 3.74 | Cognitive-disruptive effects of the psychotomimetic phencyclidine and attenuation by atypical antipsychotic medications in rats. ( Amitai, N; Markou, A; Semenova, S, 2007) |
| "After a switch from previous treatment to open-label ziprasidone more than half of patients with schizophrenia experienced sustained clinical remission over 6 months and 32% of the patients achieving remission experienced a concurrent NP improvement." | 3.74 | The relationship between symptomatic remission and neuropsychological improvement in schizophrenia patients switched to treatment with ziprasidone. ( Bowie, CR; Buckley, PF; Harvey, PD; Loebel, A, 2007) |
| "Sixty-seven outpatients with schizophrenia receiving stable doses of risperidone or haloperidol were evaluated for akathisia and other extrapyramidal side effects." | 3.74 | Association of subjective cognitive dysfunction with akathisia in patients receiving stable doses of risperidone or haloperidol. ( Byun, HJ; Kim, JH, 2007) |
| "One hundred patients with schizophrenia or schizoaffective disorder participated in an 8 week, double-blind study of risperidone, olanzapine, and haloperidol." | 3.74 | Social cognition [corrected] and neurocognition: effects of risperidone, olanzapine, and haloperidol. ( Braff, DL; Erhart, S; Green, MF; Kee, KS; Marder, SR; Mintz, J; Reist, C; Sergi, MJ; Widmark, C, 2007) |
| "Gains from earning rates for employed persons with schizophrenia, savings in informal caregiver costs and other human benefits could justify an incremental cost of 19,609 US dollars for each additional employable person prescribed risperidone." | 3.72 | Future employability, a new approach to cost-effectiveness analysis of antipsychotic therapy. ( Ganguly, R; Martin, BC; Miller, LS, 2003) |
| "Our results support the previously reported positive impact of atypical antipsychotics, particularly olanzapine, in patients with schizophrenia." | 3.72 | Effectiveness of antipsychotic treatments for schizophrenia: interim 6-month analysis from a prospective observational study (IC-SOHO) comparing olanzapine, quetiapine, risperidone, and haloperidol. ( Bitter, I; Boland, J; Dossenbach, M; el Mahfoud Kessaci, M; Erol, A; Hodge, A; O'Halloran, RA; Shaheen, MO; Sunbol, MM, 2004) |
| "P50 suppression of 13 patients with schizophrenia receiving clinically effective doses of clozapine, olanzapine, or risperidone (classified as atypical antipsychotic medications) was compared to that of 13 patients receiving conventional antipsychotic medications." | 3.70 | Normal P50 suppression in schizophrenia patients treated with atypical antipsychotic medications. ( Braff, DL; Cadenhead, KS; Clementz, BA; Geyer, MA; Light, GA, 2000) |
| "56 male subjects with paranoid schizophrenia were included in the study." | 2.77 | Double-blind placebo-controlled randomized efficacy and safety trial of add-on treatment of dimebon plus risperidone in schizophrenic patients during transition from acute psychotic episode to remission. ( Beniashvili, AG; Lepilkina, TA; Morozova, MA; Rupchev, GE, 2012) |
| "Duration of untreated psychosis (DUP) has been significantly associated with poor clinical and social outcomes in First Episode Psychosis (FEP) patients, but an association with cognitive outcomes has not been clearly established." | 2.77 | Duration of untreated negative and positive symptoms of psychosis and cognitive impairment in first episode psychosis. ( Campos, MS; Cuesta, MJ; García de Jalón, E; Ibáñez, B; Peralta, V; Sánchez-Torres, AM, 2012) |
| "CATIE-AD included 421 outpatients with Alzheimer's disease and psychosis or agitated/aggressive behavior who were randomly assigned to receive masked, flexible-dose olanzapine, quetiapine, risperidone, or placebo." | 2.76 | Cognitive effects of atypical antipsychotic medications in patients with Alzheimer's disease: outcomes from CATIE-AD. ( Dagerman, KS; Hsiao, JK; Keefe, RS; Lebowitz, BD; Lyketsos, CG; Mack, WJ; Sano, M; Schneider, LS; Stroup, TS; Sultzer, DL; Tariot, PN; Vigen, CL; Zheng, L, 2011) |
| "Clinical trials for the treatment of schizophrenia now often include cognitive assessments in addition to clinical ratings of symptoms." | 2.71 | Cross-national cognitive assessment in schizophrenia clinical trials: a feasibility study. ( Artiola i Fortuny, L; De Smedt, G; Harvey, PD; Vester-Blockland, E, 2003) |
| "Risperidone was associated with rapid, significant improvement on the conduct problem subscale score of the Nisonger Child Behavior Rating Form in patients previously treated with placebo; improvement was maintained during long-term treatment and in patients previously given risperidone." | 2.71 | Long-term, open-label study of risperidone in children with severe disruptive behaviors and below-average IQ. ( Aman, MG; Derivan, A; Eerdekens, M; Findling, RL; Lyons, B, 2004) |
| " The failure to confirm previous claims of greater improvement on either risperidone or olanzapine in patients with a first episode of psychosis may be the result of methodological bias introduced by unequal dosing between the two drugs or the use of chronically ill and treatment-refractory patients in previous studies." | 2.71 | A comparison of two novel antipsychotics in first episode non-affective psychosis: one-year outcome on symptoms, motor side effects and cognition. ( Haricharan, R; Malla, A; Manchanda, R; Norman, R; Scholten, D; Takhar, J; Townsend, L, 2004) |
| "Risperidone was well tolerated and effective in the long-term treatment of disruptive behavior disorders in children with subaverage intelligence." | 2.71 | Risperidone in children with disruptive behavior disorders and subaverage intelligence: a 1-year, open-label study of 504 patients. ( Croonenberghs, J; De Smedt, G; Fegert, JM; Findling, RL; Van Dongen, S, 2005) |
| "Risperidone treatment, however, was more effective in the reduction of negative symptoms." | 2.71 | The effect of neuroleptic treatments on executive function and symptomatology in schizophrenia: a 1-year follow up study. ( Cohen, H; Pourcher, E; Rémillard, S, 2005) |
| "Guanfacine has demonstrated efficacy in reversing working memory deficits in non-human primate." | 2.70 | Guanfacine treatment of cognitive impairment in schizophrenia. ( Adler, DN; Davis, KL; Friedman, JI; Harvey, PD; Kemether, E; Parrella, M; Temporini, HD; White, L, 2001) |
| "Treatment on risperidone also resulted in significant reduction in the PANSS score." | 2.70 | The effect of risperidone on cognitive functioning in a sample of Asian patients with schizophrenia in Singapore. ( Chan, YH; Chong, SA; Chua, L; Ng, VP; Pang, E, 2001) |
| "Risperidone treatment was well tolerated, and no clinically relevant changes in EPS." | 2.70 | Effect of risperidone on behavioral and psychological symptoms and cognitive function in dementia. ( Ertl, MG; Haushofer, M; Kraxberger, E; Masching, AJ; Rainer, MK, 2001) |
| " Subjective impairment, as assessed with the subscale 'mental functioning', was significantly correlated with greater conventional neuroleptic dosage after controlling for psychopathology (P<0." | 2.70 | Relationship between neuroleptic dosage and subjective cognitive dysfunction in schizophrenic patients treated with either conventional or atypical neuroleptic medication. ( Krausz, M; Moritz, S; Naber, D; Woodward, TS, 2002) |
| "Risperidone-treated subjects with a greater degree of acute mood change were both 3." | 2.69 | The course of depressive symptoms in predicting relapse in schizophrenia: a double-blind, randomized comparison of olanzapine and risperidone. ( Andersen, SW; Tollefson, GD; Tran, PV, 1999) |
| " Thus, antipsychotic dose and dosing interval should be optimized for each patient." | 2.52 | [Optimal Antipsychotic Dose and Dosing Interval in the Treatment of Schizophrenia]. ( Takeuchi, H, 2015) |
| "Studies in schizophrenia have used different tasks that tap different processes within the working memory." | 2.44 | [Working memory in schizophrenia: a review]. ( Kebir, O; Tabbane, K, 2008) |
| "Risperidone has relatively consistent positive effects on working memory, executive functioning, and attention, whereas improvement in verbal learning and memory was inconsistent." | 2.40 | The effects of clozapine, risperidone, and olanzapine on cognitive function in schizophrenia. ( McGurk, SR; Meltzer, HY, 1999) |
| "Cariprazine is a dopamine D3/D2 receptor partial agonist with preferential binding to D3 receptors, recently approved by the FDA for the treatment of schizophrenia and manic or mixed episodes associated with bipolar I disorder." | 1.43 | Effects of cariprazine, a novel antipsychotic, on cognitive deficit and negative symptoms in a rodent model of schizophrenia symptomatology. ( Adham, N; Ferguson, P; Grayson, B; Gyertyán, I; Kiss, B; Neill, JC, 2016) |
| "UHDRS (Unified Huntington's Disease Rating Scale) motor scores were obtained from medical records as an index of disease progression." | 1.42 | Examining Huntington's disease patient and informant concordance on frontally mediated behaviors. ( Cimino, CR; Hergert, DC; Sanchez-Ramos, J, 2015) |
| "Risperidone treatment restored increased DARPP-32 phosphorylation in the striatum and CA1 regions of NVH-lesioned rats but did not rescue CaMKII and PKCα autophosphorylation." | 1.39 | Decreased CaMKII and PKC activities in specific brain regions are associated with cognitive impairment in neonatal ventral hippocampus-lesioned rats. ( Fukunaga, K; Moriguchi, S; Nakagawasai, O; Onogi, H; Shioda, N; Tadano, T; Tan-No, K; Yabuki, Y, 2013) |
| "A shorter duration of untreated psychosis has been associated with better prognosis in schizophrenia." | 1.39 | Mismatch negativity and cognitive performance for the prediction of psychosis in subjects with at-risk mental state. ( Higuchi, Y; Kawasaki, Y; Miyanishi, T; Seo, T; Sumiyoshi, T; Suzuki, M, 2013) |
| "Family history of psychiatric illness and the presence of obstetric complications were estimated by a semistructured questionnaire." | 1.31 | Does risperidone act better in schizophrenic patients who have a family or obstetric history? ( Borkowska, A; Rybakowski, JK, 2002) |
| "A positive family history of Huntington's disease and DNA analysis helped to establish the diagnosis." | 1.30 | Psychiatric and neuropsychological abnormalities in Huntington's disease: a case study. ( Brafman, I; Brenner, R; Madhusoodanan, S; Moise, D; Sindagi, J, 1998) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 23 (13.94) | 18.2507 |
| 2000's | 94 (56.97) | 29.6817 |
| 2010's | 46 (27.88) | 24.3611 |
| 2020's | 2 (1.21) | 2.80 |
| Authors | Studies |
|---|---|
| Yabuki, Y | 2 |
| Wu, L | 2 |
| Fukunaga, K | 2 |
| Wu, ZW | 1 |
| Shi, H | 1 |
| Chen, DC | 2 |
| Chen, S | 1 |
| Xiu, MH | 1 |
| Zhang, XY | 2 |
| Setién-Suero, E | 1 |
| Ortiz-García de la Foz, V | 2 |
| Suárez-Pinilla, P | 1 |
| Crespo-Facorro, B | 4 |
| Ayesa-Arriola, R | 2 |
| Xue, F | 1 |
| Chen, YC | 1 |
| Zhou, CH | 1 |
| Wang, Y | 1 |
| Cai, M | 1 |
| Yan, WJ | 1 |
| Wu, R | 2 |
| Wang, HN | 1 |
| Peng, ZW | 1 |
| Takeuchi, H | 2 |
| Suzuki, T | 2 |
| Remington, G | 1 |
| Bies, RR | 3 |
| Abe, T | 1 |
| Graff-Guerrero, A | 1 |
| Watanabe, K | 2 |
| Mimura, M | 2 |
| Uchida, H | 2 |
| Suzuki, H | 2 |
| Gen, K | 2 |
| Inoue, Y | 1 |
| Hibino, H | 1 |
| Mikami, A | 1 |
| Matsumoto, H | 1 |
| Mikami, K | 1 |
| Liu, F | 1 |
| Guo, X | 1 |
| Ou, J | 1 |
| Zheng, Y | 1 |
| Zhang, B | 1 |
| Xie, L | 1 |
| Zhang, L | 1 |
| Yang, L | 1 |
| Yang, S | 1 |
| Yang, J | 1 |
| Ruan, Y | 1 |
| Zeng, Y | 1 |
| Xu, X | 1 |
| Zhao, J | 2 |
| Matsuda, Y | 1 |
| Sato, S | 1 |
| Iwata, K | 1 |
| Furukawa, S | 1 |
| Hatsuse, N | 1 |
| Watanabe, Y | 1 |
| Anzai, N | 1 |
| Kishimoto, T | 1 |
| Ikebuchi, E | 1 |
| Karamihalev, S | 1 |
| Prickaerts, J | 1 |
| van Goethem, NP | 1 |
| Molina, V | 1 |
| Taboada, D | 1 |
| Aragüés, M | 1 |
| Hernández, JA | 1 |
| Sanz-Fuentenebro, J | 1 |
| Phelps, TI | 1 |
| Bondi, CO | 1 |
| Ahmed, RH | 1 |
| Olugbade, YT | 1 |
| Kline, AE | 1 |
| Heller, HC | 1 |
| Salehi, A | 1 |
| Chuluun, B | 1 |
| Das, D | 1 |
| Lin, B | 1 |
| Moghadam, S | 1 |
| Garner, CC | 1 |
| Colas, D | 1 |
| Han, M | 1 |
| Tan, YL | 1 |
| Song, CS | 1 |
| Yu, YH | 1 |
| Huang, XF | 1 |
| Hergert, DC | 1 |
| Sanchez-Ramos, J | 1 |
| Cimino, CR | 1 |
| Trampush, JW | 1 |
| Lencz, T | 3 |
| DeRosse, P | 1 |
| John, M | 1 |
| Gallego, JA | 1 |
| Petrides, G | 1 |
| Hassoun, Y | 1 |
| Zhang, JP | 1 |
| Addington, J | 2 |
| Kellner, CH | 1 |
| Tohen, M | 1 |
| Burdick, KE | 3 |
| Goldberg, TE | 5 |
| Kane, JM | 5 |
| Robinson, DG | 3 |
| Malhotra, AK | 3 |
| Neill, JC | 1 |
| Grayson, B | 1 |
| Kiss, B | 1 |
| Gyertyán, I | 1 |
| Ferguson, P | 1 |
| Adham, N | 1 |
| Zhang, Y | 1 |
| Chao, YY | 1 |
| Ma, J | 1 |
| Yang, YF | 1 |
| Zhao, JY | 1 |
| Du, YH | 1 |
| Li, WW | 1 |
| Song, XQ | 1 |
| Lü, LX | 1 |
| Feng, X | 1 |
| Li, T | 1 |
| Sun, B | 1 |
| Khan, MZ | 1 |
| He, L | 1 |
| Sultzer, DL | 2 |
| Davis, SM | 2 |
| Tariot, PN | 2 |
| Dagerman, KS | 2 |
| Lebowitz, BD | 2 |
| Lyketsos, CG | 2 |
| Rosenheck, RA | 2 |
| Hsiao, JK | 3 |
| Lieberman, JA | 6 |
| Schneider, LS | 2 |
| Kebir, O | 1 |
| Tabbane, K | 1 |
| Snyder, PJ | 1 |
| Jackson, CE | 1 |
| Piskulic, D | 1 |
| Olver, J | 1 |
| Norman, T | 1 |
| Maruff, P | 1 |
| Aman, MG | 3 |
| Hollway, JA | 1 |
| McDougle, CJ | 2 |
| Scahill, L | 2 |
| Tierney, E | 2 |
| McCracken, JT | 2 |
| Arnold, LE | 2 |
| Vitiello, B | 3 |
| Ritz, L | 1 |
| Gavaletz, A | 1 |
| Cronin, P | 1 |
| Swiezy, N | 1 |
| Wheeler, C | 1 |
| Koenig, K | 1 |
| Ghuman, JK | 1 |
| Posey, DJ | 1 |
| Akhondzadeh, S | 1 |
| Mohammadi, N | 1 |
| Noroozian, M | 1 |
| Karamghadiri, N | 1 |
| Ghoreishi, A | 1 |
| Jamshidi, AH | 1 |
| Forghani, S | 1 |
| Houthoofd, SA | 1 |
| Morrens, M | 1 |
| Sabbe, BG | 1 |
| Levine, SZ | 1 |
| Rabinowitz, J | 4 |
| Morozova, MA | 2 |
| Beniashvili, AG | 2 |
| Rupchev, GE | 2 |
| Lepilkina, TA | 2 |
| Starostin, DS | 1 |
| Brusov, OS | 1 |
| McCormack, J | 1 |
| Napolitano, B | 1 |
| Patel, RC | 2 |
| Sevy, SM | 1 |
| Goldman, R | 1 |
| González-Blanch, C | 1 |
| Alvarez-Jiménez, M | 1 |
| Rodríguez-Sánchez, JM | 2 |
| Pérez-Iglesias, R | 2 |
| Pelayo-Terán, JM | 1 |
| Martínez-García, O | 2 |
| Vázquez-Barquero, JL | 3 |
| Moncrieff, J | 1 |
| Cohen, D | 1 |
| Mason, JP | 1 |
| Gupta, M | 1 |
| Bhatnagar, P | 1 |
| Grover, S | 1 |
| Kaur, H | 1 |
| Baghel, R | 1 |
| Bhasin, Y | 1 |
| Chauhan, C | 1 |
| Verma, B | 1 |
| Manduva, V | 1 |
| Mukherjee, O | 1 |
| Purushottam, M | 1 |
| Sharma, A | 1 |
| Jain, S | 1 |
| Brahmachari, SK | 1 |
| Kukreti, R | 1 |
| Mata, I | 1 |
| Ayesa, R | 1 |
| Ramirez-Bonilla, M | 1 |
| Behere, RV | 1 |
| Venkatasubramanian, G | 1 |
| Arasappa, R | 1 |
| Reddy, N | 1 |
| Gangadhar, BN | 1 |
| McClure, MM | 1 |
| Koenigsberg, HW | 1 |
| Reynolds, D | 1 |
| Goodman, M | 1 |
| New, A | 1 |
| Trestman, R | 1 |
| Silverman, J | 1 |
| Harvey, PD | 13 |
| Siever, LJ | 1 |
| Lipkovich, IA | 1 |
| Deberdt, W | 1 |
| Csernansky, JG | 2 |
| Sabbe, B | 1 |
| Keefe, RS | 7 |
| Kollack-Walker, S | 1 |
| Kim, SW | 2 |
| Shin, IS | 2 |
| Kim, JM | 2 |
| Lee, SH | 2 |
| Lee, YH | 2 |
| Yang, SJ | 1 |
| Yoon, JS | 2 |
| Schnider, A | 1 |
| Guggisberg, A | 1 |
| Nahum, L | 1 |
| Gabriel, D | 1 |
| Morand, S | 1 |
| Guénolé, F | 1 |
| D'Souza, DC | 1 |
| Patkar, AA | 1 |
| Youakim, JM | 1 |
| Tiller, JM | 1 |
| Yang, R | 1 |
| Lindenmayer, JP | 2 |
| Khan, A | 1 |
| Fox, KH | 1 |
| Cucchiaro, J | 1 |
| Siu, C | 1 |
| Loebel, A | 2 |
| Cho, SJ | 1 |
| Yook, K | 1 |
| Kim, B | 1 |
| Choi, TK | 1 |
| Lee, KS | 1 |
| Kim, YW | 1 |
| Lee, JE | 1 |
| Suh, S | 1 |
| Yook, KH | 1 |
| Ortega-Alvaro, A | 1 |
| Aracil-Fernández, A | 1 |
| García-Gutiérrez, MS | 1 |
| Navarrete, F | 1 |
| Manzanares, J | 1 |
| Vigen, CL | 1 |
| Mack, WJ | 1 |
| Sano, M | 1 |
| Stroup, TS | 2 |
| Zheng, L | 1 |
| Yasui-Furukori, N | 1 |
| Kaneda, A | 1 |
| Sugawara, N | 1 |
| Tomita, T | 1 |
| Kaneko, S | 1 |
| Marquis, KL | 1 |
| Comery, TA | 1 |
| Jow, F | 1 |
| Navarra, RL | 1 |
| Grauer, SM | 1 |
| Pulicicchio, C | 1 |
| Kelley, C | 1 |
| Brennan, JA | 1 |
| Roncarati, R | 1 |
| Scali, C | 1 |
| Haydar, S | 1 |
| Ghiron, C | 1 |
| Terstappen, GC | 1 |
| Dunlop, J | 1 |
| Koychev, I | 1 |
| McMullen, K | 1 |
| Lees, J | 1 |
| Dadhiwala, R | 1 |
| Grayson, L | 1 |
| Perry, C | 1 |
| Schmechtig, A | 1 |
| Walters, J | 1 |
| Craig, KJ | 1 |
| Dawson, GR | 1 |
| Dourish, CT | 1 |
| Ettinger, U | 1 |
| Wilkinson, L | 1 |
| Williams, S | 1 |
| Deakin, JF | 1 |
| Barkus, E | 1 |
| Sakurai, H | 1 |
| Stroup, ST | 1 |
| Rajji, TK | 1 |
| Mamo, DC | 1 |
| Pollock, BG | 4 |
| Bachman, P | 1 |
| Jalbrzikowski, M | 1 |
| Bearden, CE | 1 |
| Frazier, JA | 1 |
| Giuliano, AJ | 1 |
| Johnson, JL | 1 |
| Yakutis, L | 1 |
| Youngstrom, EA | 1 |
| Breiger, D | 1 |
| Sikich, L | 1 |
| Findling, RL | 3 |
| McClellan, J | 1 |
| Hamer, RM | 4 |
| Hooper, SR | 1 |
| Chung, YC | 1 |
| Lee, JH | 1 |
| Kim, SY | 1 |
| Bae, KY | 1 |
| Remberk, B | 1 |
| Namysłowska, I | 1 |
| Rybakowski, F | 1 |
| Roiz-Santiáñez, R | 1 |
| Tordesillas-Gutiérrez, D | 1 |
| Gutiérrez, A | 1 |
| Tabarés-Seisdedos, R | 1 |
| Croarkin, PE | 1 |
| Daskalakis, ZJ | 1 |
| Zaytseva, Y | 1 |
| Gurovich, IY | 1 |
| Goland, E | 1 |
| Storozhakova, YA | 1 |
| Faries, D | 1 |
| Ascher-Svanum, H | 1 |
| Phillips, G | 1 |
| Nyhuis, AW | 1 |
| Sugihara, T | 1 |
| Stauffer, V | 1 |
| Kinon, BJ | 1 |
| Cuesta, MJ | 1 |
| García de Jalón, E | 1 |
| Campos, MS | 1 |
| Ibáñez, B | 1 |
| Sánchez-Torres, AM | 1 |
| Peralta, V | 1 |
| Geffen, Y | 1 |
| Keefe, R | 1 |
| Anand, R | 1 |
| Davidson, M | 2 |
| Pandina, G | 1 |
| Bilder, R | 1 |
| Turkoz, I | 2 |
| Alphs, L | 1 |
| Nakagawasai, O | 1 |
| Moriguchi, S | 1 |
| Shioda, N | 1 |
| Onogi, H | 1 |
| Tan-No, K | 1 |
| Tadano, T | 1 |
| Bourque, J | 1 |
| Lakis, N | 1 |
| Champagne, J | 1 |
| Stip, E | 4 |
| Lalonde, P | 1 |
| Lipp, O | 1 |
| Mendrek, A | 2 |
| Higuchi, Y | 1 |
| Sumiyoshi, T | 2 |
| Seo, T | 1 |
| Miyanishi, T | 1 |
| Kawasaki, Y | 1 |
| Suzuki, M | 1 |
| Artiola i Fortuny, L | 1 |
| Vester-Blockland, E | 1 |
| De Smedt, G | 2 |
| Broerse, A | 1 |
| Crawford, TJ | 1 |
| den Boer, JA | 1 |
| de Haan, L | 1 |
| van Amelsvoort, T | 1 |
| Aguglia, E | 1 |
| De Vanna, M | 1 |
| Onor, ML | 1 |
| Ferrara, D | 1 |
| Borkowska, A | 2 |
| Rybakowski, JK | 2 |
| Meltzer, HY | 5 |
| Green, MF | 5 |
| McGurk, SR | 3 |
| Ganguly, R | 1 |
| Miller, LS | 1 |
| Martin, BC | 1 |
| Bokszanska, A | 1 |
| Martin, G | 1 |
| Vanstraelen, M | 1 |
| Holt, G | 1 |
| Bouras, N | 1 |
| Taylor, D | 1 |
| Napolitano, JA | 1 |
| Mao, L | 3 |
| Gharabawi, G | 3 |
| Brunnauer, A | 1 |
| Geiger, E | 1 |
| Laux, G | 1 |
| Szekeres, G | 1 |
| Kéri, S | 1 |
| Juhász, A | 1 |
| Rimanóczy, A | 1 |
| Szendi, I | 1 |
| Czimmer, C | 1 |
| Janka, Z | 1 |
| Lane, HY | 1 |
| Lin, CC | 1 |
| Huang, CH | 1 |
| Chang, YC | 1 |
| Hsu, SK | 1 |
| Chang, WH | 1 |
| Bellack, AS | 1 |
| Schooler, NR | 2 |
| Marder, SR | 3 |
| Brown, CH | 1 |
| Yang, Y | 1 |
| Heydebrand, G | 1 |
| Weiser, M | 1 |
| Hoff, AL | 1 |
| DeLisi, LE | 1 |
| Eerdekens, M | 2 |
| Derivan, A | 1 |
| Lyons, B | 1 |
| Dossenbach, M | 1 |
| Erol, A | 1 |
| el Mahfoud Kessaci, M | 1 |
| Shaheen, MO | 1 |
| Sunbol, MM | 1 |
| Boland, J | 1 |
| Hodge, A | 1 |
| O'Halloran, RA | 1 |
| Bitter, I | 1 |
| Parellada, E | 1 |
| Baeza, I | 1 |
| de Pablo, J | 1 |
| Martínez, G | 1 |
| Wirshing, WC | 1 |
| Wirshing, DA | 1 |
| Mintz, J | 2 |
| Kern, R | 1 |
| Zannino, G | 1 |
| Gargiulo, A | 1 |
| Lamenza, F | 1 |
| Marotta, MG | 1 |
| Barzotti, T | 1 |
| Silvestri, A | 1 |
| Ettorre, E | 1 |
| Marigliano, V | 1 |
| Segal, J | 1 |
| Szabo, CP | 1 |
| du Toit, J | 1 |
| Malla, A | 1 |
| Norman, R | 1 |
| Scholten, D | 1 |
| Townsend, L | 1 |
| Manchanda, R | 1 |
| Takhar, J | 1 |
| Haricharan, R | 1 |
| Croonenberghs, J | 1 |
| Fegert, JM | 1 |
| Van Dongen, S | 1 |
| Mulsant, BH | 2 |
| Gharabawi, GM | 2 |
| Bossie, CA | 1 |
| Martinez, RA | 1 |
| Tune, LE | 2 |
| Greenspan, AJ | 1 |
| Bastean, JN | 1 |
| Moríñigo, A | 1 |
| Blanco, M | 1 |
| Labrador, J | 1 |
| Martín, J | 1 |
| Noval, D | 1 |
| Li, X | 1 |
| May, RS | 1 |
| Tolbert, LC | 1 |
| Jackson, WT | 1 |
| Flournoy, JM | 1 |
| Baxter, LR | 1 |
| Garver, DL | 1 |
| Holcomb, JA | 1 |
| Christensen, JD | 1 |
| Bennouna, M | 1 |
| Greene, VB | 1 |
| Defranoux, L | 1 |
| Rémillard, S | 1 |
| Pourcher, E | 1 |
| Cohen, H | 1 |
| Pavuluri, MN | 1 |
| Schenkel, LS | 1 |
| Aryal, S | 1 |
| Harral, EM | 1 |
| Hill, SK | 2 |
| Herbener, ES | 1 |
| Sweeney, JA | 3 |
| Guaiana, G | 1 |
| Markova, I | 1 |
| Zhong, KX | 1 |
| Sweitzer, DE | 1 |
| Chinnasamy, D | 1 |
| Rudd, R | 1 |
| Velakoulis, D | 1 |
| Chew, ML | 1 |
| Lehman, ME | 1 |
| Greenspan, A | 1 |
| Kirshner, MA | 1 |
| Kapur, S | 1 |
| Patterson, TL | 1 |
| Potter, LS | 1 |
| Zhong, K | 1 |
| Brecher, M | 1 |
| Böker, H | 1 |
| Brandenberger, M | 1 |
| Schopper, C | 1 |
| Burns, A | 1 |
| De Deyn, PP | 1 |
| Akdede, BB | 1 |
| Anil Yağcioğlu, AE | 1 |
| Alptekin, K | 1 |
| Turgut, TI | 1 |
| Tümüklü, M | 1 |
| Yazici, MK | 1 |
| Jayathilake, K | 1 |
| Tunca, Z | 1 |
| Göğüş, A | 1 |
| Fischer, RB | 1 |
| Limosin, F | 1 |
| Didriksen, M | 1 |
| Skarsfeldt, T | 1 |
| Arnt, J | 1 |
| Goff, DC | 1 |
| Lamberti, JS | 1 |
| Leon, AC | 1 |
| Miller, AL | 1 |
| Patel, J | 1 |
| Manschreck, T | 1 |
| Freudenreich, O | 1 |
| Johnson, SA | 1 |
| Amitai, N | 1 |
| Semenova, S | 1 |
| Markou, A | 1 |
| Buckley, PF | 1 |
| Bowie, CR | 1 |
| Gurpegui, M | 1 |
| Alvarez, E | 1 |
| Bousoño, M | 1 |
| Ciudad, A | 1 |
| Carlos Gómez, J | 1 |
| Olivares, JM | 1 |
| Bilder, RM | 1 |
| Palmer, BW | 1 |
| Gold, JM | 1 |
| Capuano, G | 1 |
| McEvoy, JP | 3 |
| Swartz, MS | 1 |
| Perkins, DO | 3 |
| Davis, CE | 1 |
| Siuciak, JA | 1 |
| McCarthy, SA | 1 |
| Martin, AN | 1 |
| Chapin, DS | 1 |
| Stock, J | 1 |
| Nadeau, DM | 1 |
| Kantesaria, S | 1 |
| Bryce-Pritt, D | 1 |
| McLean, S | 1 |
| Savina, I | 1 |
| Beninger, RJ | 1 |
| Silver, H | 1 |
| Goodman, C | 1 |
| Ito, T | 1 |
| Meguro, K | 1 |
| Akanuma, K | 1 |
| Meguro, M | 1 |
| Lee, E | 1 |
| Kasuya, M | 1 |
| Ishii, H | 1 |
| Mori, E | 1 |
| Drozdz, W | 1 |
| Gu, H | 2 |
| Sukhodolsky, DG | 1 |
| Gadow, KD | 1 |
| Williams White, S | 1 |
| Lecavalier, L | 1 |
| Hassman, H | 1 |
| Mahmoud, RA | 1 |
| Engelhart, LM | 1 |
| Kim, JH | 1 |
| Byun, HJ | 1 |
| Sergi, MJ | 1 |
| Widmark, C | 1 |
| Reist, C | 1 |
| Erhart, S | 1 |
| Braff, DL | 2 |
| Kee, KS | 1 |
| Goldman, RS | 1 |
| Woerner, MG | 1 |
| Reilly, JL | 1 |
| Harris, MS | 1 |
| Khine, T | 1 |
| Terry, AV | 1 |
| Gearhart, DA | 1 |
| Warner, S | 1 |
| Hohnadel, EJ | 1 |
| Middlemore, ML | 1 |
| Zhang, G | 1 |
| Bartlett, MG | 1 |
| Mahadik, SP | 1 |
| Bossie, C | 1 |
| Kujawa, M | 1 |
| Mahmoud, R | 1 |
| Simpson, G | 1 |
| Weiden, PJ | 1 |
| Goetghebeur, P | 1 |
| Dias, R | 1 |
| Singh, D | 1 |
| Forlano, R | 1 |
| Athey, R | 1 |
| Weinberger, DR | 2 |
| Daniel, DG | 1 |
| Kleinman, JE | 1 |
| Pickar, D | 1 |
| Lubick, LJ | 1 |
| Williams, TS | 1 |
| Lussier, I | 2 |
| Borison, RL | 1 |
| Rossi, A | 1 |
| Mancini, F | 1 |
| Stratta, P | 1 |
| Mattei, P | 1 |
| Gismondi, R | 1 |
| Pozzi, F | 1 |
| Casacchia, M | 1 |
| Morehead, DB | 1 |
| Addington, D | 2 |
| Lavretsky, H | 1 |
| Sultzer, D | 1 |
| Tracy, JI | 1 |
| Monaco, CA | 1 |
| Abraham, G | 1 |
| Josiassen, RC | 1 |
| Magnuson, TM | 1 |
| Keller, BK | 1 |
| Burke, WJ | 1 |
| Madhusoodanan, S | 1 |
| Brenner, R | 1 |
| Moise, D | 1 |
| Sindagi, J | 1 |
| Brafman, I | 1 |
| Iskander, A | 1 |
| Park, M | 1 |
| Apergi, FS | 1 |
| Czobor, P | 1 |
| Smith, R | 1 |
| Allen, D | 1 |
| Hawkins, KA | 1 |
| Mohamed, S | 1 |
| Woods, SW | 1 |
| Purdon, SE | 2 |
| Breier, A | 2 |
| Tsuang, MT | 1 |
| Stone, WS | 1 |
| Seidman, LJ | 1 |
| Faraone, SV | 1 |
| Zimmet, S | 1 |
| Wojcik, J | 1 |
| Kelleher, JP | 1 |
| Green, AI | 1 |
| Tollefson, GD | 2 |
| Andersen, SW | 1 |
| Tran, PV | 1 |
| Ngan, E | 1 |
| Liddle, P | 1 |
| Jones, BD | 1 |
| Labelle, A | 1 |
| David, SR | 1 |
| Light, GA | 1 |
| Geyer, MA | 1 |
| Clementz, BA | 1 |
| Cadenhead, KS | 1 |
| Curtis, RC | 1 |
| Resch, DS | 1 |
| Moriarty, PJ | 1 |
| Serper, MR | 1 |
| Schnur, E | 1 |
| Lieber, D | 1 |
| Bhana, N | 1 |
| Foster, RH | 1 |
| Olney, R | 1 |
| Plosker, GL | 1 |
| Friedman, JI | 2 |
| Adler, DN | 2 |
| Temporini, HD | 1 |
| Kemether, E | 1 |
| White, L | 2 |
| Parrella, M | 2 |
| Davis, KL | 2 |
| Chua, L | 1 |
| Chong, SA | 1 |
| Pang, E | 1 |
| Ng, VP | 1 |
| Chan, YH | 1 |
| Rainer, MK | 1 |
| Masching, AJ | 1 |
| Ertl, MG | 1 |
| Kraxberger, E | 1 |
| Haushofer, M | 1 |
| Moritz, S | 1 |
| Woodward, TS | 1 |
| Krausz, M | 1 |
| Naber, D | 1 |
| Kuroki, T | 1 |
| Tashiro, N | 1 |
| Howanitz, E | 1 |
| Brenner, G | 1 |
| Temporini, H | 1 |
| Sharma, T | 1 |
| Weiss, E | 1 |
| Kemmler, G | 1 |
| Fleischhacker, WW | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Double-Blind,Randomized Study of Minocycline for the Treatment of Negative and Cognitive Symptoms in Schizophrenia[NCT01493622] | Phase 4 | 78 participants (Actual) | Interventional | 2010-06-30 | Completed | ||
| Comparative Effectiveness of Antipsychotic Medications in Patients With Alzheimer's Disease (CATIE Alzheimer's Disease Trial)[NCT00015548] | 450 participants | Interventional | 2001-03-31 | Completed | |||
| A 4-Week, Double-Blind, Placebo-Controlled, Parallel-Group, Fixed-Dosage Study to Evaluate the Efficacy and Safety of Armodafinil as Adjunctive Therapy in Adults With Cognitive Deficits Associated With Schizophrenia[NCT00487942] | Phase 2 | 60 participants (Actual) | Interventional | 2007-07-31 | Completed | ||
| Theta Burst Stimulation for Schizophrenia[NCT03288779] | 6 participants (Actual) | Interventional | 2017-10-24 | Completed | |||
| Long-Term Safety, Tolerability, and Effectiveness of Lurasidone in Subjects With Schizophrenia or Schizoaffective Disorder: A Randomized, Active Comparator-Controlled Trial[NCT00641745] | Phase 3 | 629 participants (Actual) | Interventional | 2008-03-31 | Completed | ||
| Comparative Effectiveness of Antipsychotic Medications in Patients With Schizophrenia (CATIE Schizophrenia Trial)[NCT00014001] | Phase 4 | 1,600 participants | Interventional | 2000-12-31 | Completed | ||
| Treatment of Schizophrenia and Related Disorders in Children and Adolescents[NCT00053703] | Phase 4 | 116 participants (Actual) | Interventional | 2002-02-28 | Completed | ||
| Paliperidone ER Versus Risperidone for Neurocognitive Function in Patients With Schizophrenia: a Randomized, Open-label, Controlled Trial[NCT00827840] | Phase 4 | 58 participants (Actual) | Interventional | 2008-11-30 | Completed | ||
| Socially Inappropriate Behaviour in People With First Episode Psychosis: A Caregivers' Perspective[NCT03501160] | 8 participants (Actual) | Observational | 2018-06-12 | Completed | |||
| A Six-week, Randomized, Double-blind, Placebo-controlled, Parallel Group, Multi-center, Phase II Study to Determine the Efficacy, Tolerability and Safety of Low and High Non-overlapping Dose Ranges of BL-1020 Compared to Placebo and Risperidone[NCT00567710] | Phase 2 | 360 participants (Anticipated) | Interventional | 2008-07-31 | Completed | ||
| An Exploratory Study to Assess the Effects of Fanapt® on Social Cognitive Performance[NCT01929889] | Phase 4 | 19 participants (Actual) | Interventional | 2012-04-30 | Terminated (stopped due to Low recruitment) | ||
| A Placebo-Controlled Trial of CX516 (Ampakine) Added to Clozapine, Olanzapine or Risperidone in Patients With Schizophrenia[NCT00235352] | Phase 2/Phase 3 | 105 participants (Actual) | Interventional | 2002-02-28 | Completed | ||
| Pharmacologic Augmentation of Neurocognition and Cognitive Training in Psychosis[NCT02634684] | Phase 2 | 82 participants (Actual) | Interventional | 2014-07-01 | Completed | ||
| Efficacy and Tolerability of Olanzapine, Quetiapine and Risperidone in the Treatment of First Episode Psychosis: A Randomized Double Blind 52-Week Comparison[NCT00034892] | Phase 3 | 0 participants | Interventional | 2002-03-31 | Completed | ||
| Methylphenidate for Hyperactivity and Impulsiveness in Children and Adolescents With Pervasive Developmental Disorders[NCT00025779] | 60 participants | Interventional | 2001-10-31 | Completed | |||
| Neural Mechanisms of CBT for Anxiety in Children With Autism: Randomized Controlled Trial[NCT02725619] | 70 participants (Actual) | Interventional | 2016-04-30 | Completed | |||
| Neural Mechanisms of Cognitive-Behavioral Therapy for Anxiety in Children With Autism Spectrum Disorder: A Pilot Study[NCT02225808] | 10 participants (Actual) | Interventional | 2014-08-31 | Completed | |||
| Differences in Cognitive Function Due to Acute Sedative Effects of Risperidone and Quetiapine in Stable Bipolar I Out-Patients.[NCT00097032] | Phase 3 | 30 participants (Actual) | Interventional | 2004-10-31 | Completed | ||
| The Cognitive Effects of Risperidone and Olanzapine[NCT00108368] | Phase 4 | 0 participants | Interventional | 2003-10-31 | Completed | ||
| Effectiveness of Paliperidone ER(Invega®) on Depressive Symptoms of Schizophrenia Patients: A 8-week Open-label Prospective, Non-comparative Study[NCT01399450] | Phase 4 | 11 participants (Actual) | Interventional | 2011-08-31 | Completed | ||
| Guanfacine Enhancement of Working Memory: Prospects for Augmenting Cognitive Remediation in the Schizophrenia Spectrum[NCT02524899] | Phase 2 | 45 participants (Actual) | Interventional | 2014-01-31 | Completed | ||
| The Effects of Ketamine and Guanfacine on Working Memory in Healthy Subjects[NCT01600885] | 16 participants (Actual) | Interventional | 2008-08-31 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
An actigraphy device was worn by each patient starting with the initial screening. The device continuously measured movement, allowing for an evaluation of spontaneous motor activity. Data from the actigraphy device were downloaded at each visit. The data presented here is the change from baseline to Endpoint in total activity. (NCT00487942)
Timeframe: Baseline and Week 4 or last observation after baseline
| Intervention | Counts (Mean) |
|---|---|
| Armodafinil 50 mg/Day | 175906.8 |
| Armodafinil 100 mg/Day | 45621.4 |
| Armodafinil 200 mg/Day | 144855.3 |
| Placebo | 38708.1 |
An actigraphy device was worn by each patient starting with the initial screening. The device continuously measured movement, allowing for an evaluation of spontaneous motor activity. Data from the actigraphy device were downloaded at each visit. The data presented here is the change from baseline in average activity per epoch (counts/epoch). (NCT00487942)
Timeframe: Baseline and Week 4 or last observation after baseline
| Intervention | Counts (Mean) |
|---|---|
| Armodafinil 50 mg/Day | -17.6 |
| Armodafinil 100 mg/Day | -0.7 |
| Armodafinil 200 mg/Day | 4.2 |
| Placebo | 0.8 |
An actigraphy device was worn by each patient starting with the initial screening. The device continuously measured movement, allowing for an evaluation of spontaneous motor activity. Data from the actigraphy device were downloaded at each visit. The data presented here is the change from baseline in maximum activity to Endpoint. (NCT00487942)
Timeframe: Baseline and Week 4 or last observation after baseline
| Intervention | Counts (Mean) |
|---|---|
| Armodafinil 50 mg/Day | -124.3 |
| Armodafinil 100 mg/Day | -73.2 |
| Armodafinil 200 mg/Day | 70.4 |
| Placebo | -5.9 |
An actigraphy device was worn by each patient starting with the initial screening. The device continuously measured movement, allowing for an evaluation of spontaneous motor activity. Data from the actigraphy device were downloaded at each visit. The data presented here is the change from baseline to endpoint in standard deviation of activity (counts/epoch). (NCT00487942)
Timeframe: Baseline and Week 4 or last observation after baseline
| Intervention | Counts (Mean) |
|---|---|
| Armodafinil 50 mg/Day | -5.1 |
| Armodafinil 100 mg/Day | -0.7 |
| Armodafinil 200 mg/Day | 6.0 |
| Placebo | -1.9 |
An actigraphy device was worn by each patient starting with the initial screening. The device continuously measured movement, allowing for an evaluation of spontaneous motor activity. Data from the actigraphy device were downloaded at each visit. The data presented here is the change from baseline to Endpoint in total activity. (NCT00487942)
Timeframe: Baseline and Week 4 or last observation after baseline
| Intervention | Counts (Mean) |
|---|---|
| Armodafinil 50 mg/Day | 7037.0 |
| Armodafinil 100 mg/Day | -9164.8 |
| Armodafinil 200 mg/Day | 23631.1 |
| Placebo | -24811.4 |
An actigraphy device was worn by each patient starting with the initial screening. The device continuously measured movement, allowing for an evaluation of spontaneous motor activity. Data from the actigraphy device were downloaded at each visit. The data presented here is the change from baseline to Endpoint in total activity. (NCT00487942)
Timeframe: Baseline and Week 4 or last observation after baseline
| Intervention | Counts (Mean) |
|---|---|
| Armodafinil 50 mg/Day | -41210.0 |
| Armodafinil 100 mg/Day | -16150.5 |
| Armodafinil 200 mg/Day | -5159.5 |
| Placebo | -34443.8 |
The SCoRS is an 18-item interview based assessment covering all the cognitive domains in the MATRICS Consensus Cognitive Battery except social cognition. It is administered separately to the patient and an informant (family or friend) who are asked to rate the patient's level of difficulty in performing various cognitive functions on a 4-point scale (higher rating = greater impairment). They also complete a global assessment of cognitive function on a 1-10 scale. The interviewer factors in their own assessment on both the 18-items (Total Score) and the global assessment for the final score. (NCT00487942)
Timeframe: Baseline and Week 4 or last observation after baseline
| Intervention | Units on a scale (Mean) |
|---|---|
| Armodafinil 50 mg/Day | -3.9 |
| Armodafinil 100 mg/Day | -0.7 |
| Armodafinil 200 mg/Day | -4.6 |
| Placebo | -3.1 |
ESS is a self-administered subjective measure of daytime sleepiness, based on responses to questions referring to 8 everyday situations (eg. sitting and reading, talking to someone) and reflects a patient's propensity to fall asleep in those situations. Score for the ESS range from 0 to 24 with higher scores indicating greater daytime sleepiness. Data here represents the change from Baseline to Week 1 in the ESS total score. (NCT00487942)
Timeframe: Baseline and 1 week following the start of study drug administration
| Intervention | Units on a scale (Mean) |
|---|---|
| Armodafinil 50 mg/Day | -2.2 |
| Armodafinil 100 mg/Day | -1.4 |
| Armodafinil 200 mg/Day | 0.0 |
| Placebo | -1.5 |
SANS is a clinician-rated instrument that rates the severity of negative symptoms of schizophrenia. It contains 25 items in 5 domains: affective flattening/blunting, alogia, avolition-apathy, anhedonia-asociality, attentional impairment. Items in a domain assess symptoms and a global item assesses the overall severity of the domain. Each item is scored on a 6-point severity scale(0=Not at all, 1=questionable decrease, 2=mild, 3=moderate, 4=marked, 5=severe). The total scale ranges from 0-125. Data presented here represents change in total score from Baseline to Week 1. (NCT00487942)
Timeframe: Baseline and 1 week following the start of study drug administration
| Intervention | Units on a scale (Mean) |
|---|---|
| Armodafinil 50 mg/Day | -1.4 |
| Armodafinil 100 mg/Day | -2.5 |
| Armodafinil 200 mg/Day | -2.2 |
| Placebo | -2.2 |
The BARS is a 4-item clinician-rated scale to measure the presence and severity of drug-induced akathisia. Items related to the assessment of objective akathisia, subjective awareness of restlessness, and distress related to restlessness are rated using various 4-point (0 - 3) scales. A global assessment of akathisia is rated using a 6-point (0=Absent, 1=Questionable akathisia, 2=Mild akathisia, 3=Moderate akathisia, 4=Marked akathisia, 5=Severe akathisia) scale. The total score range is from 0 to 14 with a higher score indicating more severe akathisia. (NCT00487942)
Timeframe: Baseline and 1 week following the start of study drug administration
| Intervention | Units on a scale (Mean) |
|---|---|
| Armodafinil 50 mg/Day | -0.4 |
| Armodafinil 100 mg/Day | -0.2 |
| Armodafinil 200 mg/Day | 0.0 |
| Placebo | 0.1 |
An actigraphy device was worn by each patient starting with the initial screening. The device continuously measured movement, allowing for an evaluation of spontaneous motor activity. Data from the actigraphy device were downloaded at each visit. The data presented here is the change from baseline to week 1 in total activity. (NCT00487942)
Timeframe: Baseline and Week 1
| Intervention | Counts (Mean) |
|---|---|
| Armodafinil 50 mg/Day | 92077.4 |
| Armodafinil 100 mg/Day | -28961.9 |
| Armodafinil 200 mg/Day | 18639.8 |
| Placebo | -118038 |
An actigraphy device was worn by each patient starting with the initial screening. The device continuously measured movement, allowing for an evaluation of spontaneous motor activity. Data from the actigraphy device were downloaded at each visit. The data presented here is the change from baseline in average activity per epoch (counts/epoch)to Week 1. (NCT00487942)
Timeframe: Baseline and Week 1
| Intervention | Counts (Mean) |
|---|---|
| Armodafinil 50 mg/Day | -2.3 |
| Armodafinil 100 mg/Day | 8.9 |
| Armodafinil 200 mg/Day | 2.1 |
| Placebo | 0.8 |
An actigraphy device was worn by each patient starting with the initial screening. The device continuously measured movement, allowing for an evaluation of spontaneous motor activity. Data from the actigraphy device were downloaded at each visit. The data presented here is the change from baseline to Week 1 in maximum activity. (NCT00487942)
Timeframe: Baseline and Week 1
| Intervention | Counts (Mean) |
|---|---|
| Armodafinil 50 mg/Day | -85.7 |
| Armodafinil 100 mg/Day | 14.8 |
| Armodafinil 200 mg/Day | 20.5 |
| Placebo | 6.2 |
An actigraphy device was worn by each patient starting with the initial screening. The device continuously measured movement, allowing for an evaluation of spontaneous motor activity. Data from the actigraphy device were downloaded at each visit. The data presented here is the change from baseline to Week 1 in standard deviation of activity (counts/epoch). (NCT00487942)
Timeframe: Baseline and Week 1
| Intervention | Counts (Mean) |
|---|---|
| Armodafinil 50 mg/Day | -4.3 |
| Armodafinil 100 mg/Day | 7.6 |
| Armodafinil 200 mg/Day | 4.2 |
| Placebo | 1.7 |
An actigraphy device was worn by each patient starting with the initial screening. The device continuously measured movement, allowing for an evaluation of spontaneous motor activity. Data from the actigraphy device were downloaded at each visit. The data presented here is the change from baseline to week 1 in total activity. (NCT00487942)
Timeframe: Baseline and Week 1
| Intervention | Counts (Mean) |
|---|---|
| Armodafinil 50 mg/Day | 5913.6 |
| Armodafinil 100 mg/Day | -3818.5 |
| Armodafinil 200 mg/Day | 23665.1 |
| Placebo | -12675.4 |
An actigraphy device was worn by each patient starting with the initial screening. The device continuously measured movement, allowing for an evaluation of spontaneous motor activity. Data from the actigraphy device were downloaded at each visit. The data presented here is the change from baseline to Week 1 in total activity. (NCT00487942)
Timeframe: Baseline and Week 1
| Intervention | Counts (Mean) |
|---|---|
| Armodafinil 50 mg/Day | 2419.5 |
| Armodafinil 100 mg/Day | 37665.8 |
| Armodafinil 200 mg/Day | 15892.7 |
| Placebo | 1116.3 |
The Modified Simpson Angus Scale is a clinician-rated scale to assess the presence and severity of extrapyramidal symptoms associated study drug treatment. This is a 10-item scale that focuses on rigidity. The items are rated using a 5-point (0 - 4) scale. The total score ranges between 0 and 40. The data presented here represents the change from Baseline to Week 1. (NCT00487942)
Timeframe: Baseline and 1 week following the start of study drug administration
| Intervention | Units on a scale (Mean) |
|---|---|
| Armodafinil 50 mg/Day | 0.0 |
| Armodafinil 100 mg/Day | -0.2 |
| Armodafinil 200 mg/Day | -0.1 |
| Placebo | -0.1 |
PANSS is a clinician-rated instrument that rates the severity of psychopathology in patients with schizophrenia. 7 items measure positive symptoms (eg. delusions, hallucinations), 7 items measure negative symptoms (eg. blunted affect, social withdrawal), 16 items form a General Psychopathology scale (eg. anxiety, motor retardation). Each item is scored on a 7-point severity scale: 1=absent, 2=minimal, 3=mild, 4=moderate, 5=moderate severe, 6=severe, 7=extreme. The Negative Scale score ranges from 7 to 49. The data here represents the change in Negative Rating Scale from Baseline to Week 1. (NCT00487942)
Timeframe: Baseline and 1 week following the start of study drug administration
| Intervention | Units on a scale (Mean) |
|---|---|
| Armodafinil 50 mg/Day | 0.4 |
| Armodafinil 100 mg/Day | -0.1 |
| Armodafinil 200 mg/Day | -2.5 |
| Placebo | -0.4 |
PANSS is a clinician-rated instrument that rates the severity of psychopathology in patients with schizophrenia. 7 items measure positive symptoms (eg. delusions, hallucinations), 7 items measure negative symptoms (eg. blunted affect, social withdrawal), 16 items form a General Psychopathology scale (eg. anxiety, motor retardation). Each item is scored on a 7-point severity scale: 1=absent, 2=minimal, 3=mild, 4=moderate, 5=moderate severe, 6=severe, 7=extreme. The Positive Scale score ranges from 7 to 49. The data here represents the change in Positive Rating Scale from Baseline to Week 1. (NCT00487942)
Timeframe: Baseline and 1 week following the start of study drug administration
| Intervention | Units on a scale (Mean) |
|---|---|
| Armodafinil 50 mg/Day | 0.3 |
| Armodafinil 100 mg/Day | -0.1 |
| Armodafinil 200 mg/Day | 0.3 |
| Placebo | -0.6 |
PANSS is a clinician-rated instrument that rates the severity of psychopathology in patients with schizophrenia. 7 items measure positive symptoms (eg. delusions, hallucinations), 7 items measure negative symptoms (eg. blunted affect, social withdrawal), 16 items form a General Psychopathology scale (eg. anxiety, motor retardation). Each item is scored on a 7-point severity scale: 1=absent, 2=minimal, 3=mild, 4=moderate, 5=moderate severe, 6=severe, 7=extreme. The Total score ranges from 7 to 210. The data here represents the change in Total score from Baseline to Week 1. (NCT00487942)
Timeframe: Baseline and 1 week following the start of study drug administration
| Intervention | Units on a scale (Mean) |
|---|---|
| Armodafinil 50 mg/Day | 0.5 |
| Armodafinil 100 mg/Day | -0.8 |
| Armodafinil 200 mg/Day | -4.0 |
| Placebo | -2.3 |
ESS is a self-administered subjective measure of daytime sleepiness, based on responses to questions referring to 8 everyday situations (eg. sitting and reading, talking to someone) and reflects a patient's propensity to fall asleep in those situations. Score for the ESS range from 0 to 24 with higher scores indicating greater daytime sleepiness. Data here represents the change from Baseline to Week 2 in the ESS total score. (NCT00487942)
Timeframe: Baseline and 2 weeks following the start of study drug administration
| Intervention | Units on a scale (Mean) |
|---|---|
| Armodafinil 50 mg/Day | -1.1 |
| Armodafinil 100 mg/Day | -1.6 |
| Armodafinil 200 mg/Day | 0.3 |
| Placebo | -2.1 |
SANS is a clinician-rated instrument that rates the severity of negative symptoms of schizophrenia. It contains 25 items in 5 domains: affective flattening/blunting, alogia, avolition-apathy, anhedonia-asociality, attentional impairment. Items in a domain assess symptoms and a global item assesses the overall severity of the domain. Each item is scored on a 6-point severity scale(0=Not at all, 1=questionable decrease, 2=mild, 3=moderate, 4=marked, 5=severe). The total scale ranges from 0-125. Data presented here represents change in total score from Baseline to Week 2. (NCT00487942)
Timeframe: Baseline and 2 weeks following the start of study drug administration
| Intervention | Units on a scale (Mean) |
|---|---|
| Armodafinil 50 mg/Day | 0.4 |
| Armodafinil 100 mg/Day | -4.5 |
| Armodafinil 200 mg/Day | -4.4 |
| Placebo | -6.8 |
The BARS is a 4-item clinician-rated scale to measure the presence and severity of drug-induced akathisia. Items related to the assessment of objective akathisia, subjective awareness of restlessness, and distress related to restlessness are rated using various 4-point (0 - 3) scales. A global assessment of akathisia is rated using a 6-point (0=Absent, 1=Questionable akathisia, 2=Mild akathisia, 3=Moderate akathisia, 4=Marked akathisia, 5=Severe akathisia) scale. The total score range is from 0 to 14 with a higher score indicating more severe akathisia. (NCT00487942)
Timeframe: Baseline and 2 weeks following the start of study drug administration
| Intervention | Units on a scale (Mean) |
|---|---|
| Armodafinil 50 mg/Day | 0.2 |
| Armodafinil 100 mg/Day | 0.1 |
| Armodafinil 200 mg/Day | -0.3 |
| Placebo | 0.4 |
An actigraphy device was worn by each patient starting with the initial screening. The device continuously measured movement, allowing for an evaluation of spontaneous motor activity. Data from the actigraphy device were downloaded at each visit. The data presented here is the change from baseline to Week 2 in total activity. (NCT00487942)
Timeframe: Baseline and Week 2
| Intervention | Counts (Mean) |
|---|---|
| Armodafinil 50 mg/Day | -46326.7 |
| Armodafinil 100 mg/Day | -44034.8 |
| Armodafinil 200 mg/Day | -1954.7 |
| Placebo | -78154.5 |
An actigraphy device was worn by each patient starting with the initial screening. The device continuously measured movement, allowing for an evaluation of spontaneous motor activity. Data from the actigraphy device were downloaded at each visit. The data presented here is the change from baseline in average activity per epoch (counts/epoch) to Week 2. (NCT00487942)
Timeframe: Baseline and Week 2
| Intervention | Counts (Mean) |
|---|---|
| Armodafinil 50 mg/Day | -15.4 |
| Armodafinil 100 mg/Day | -7.9 |
| Armodafinil 200 mg/Day | -7.2 |
| Placebo | 13.1 |
An actigraphy device was worn by each patient starting with the initial screening. The device continuously measured movement, allowing for an evaluation of spontaneous motor activity. Data from the actigraphy device were downloaded at each visit. The data presented here is the change from baseline to Week 2 in maximum activity. (NCT00487942)
Timeframe: Baseline and Week 2
| Intervention | Counts (Mean) |
|---|---|
| Armodafinil 50 mg/Day | -152.7 |
| Armodafinil 100 mg/Day | -146.3 |
| Armodafinil 200 mg/Day | 11.8 |
| Placebo | -28.4 |
An actigraphy device was worn by each patient starting with the initial screening. The device continuously measured movement, allowing for an evaluation of spontaneous motor activity. Data from the actigraphy device were downloaded at each visit. The data presented here is the change from baseline to Week 2 in standard deviation of activity (counts/epoch). (NCT00487942)
Timeframe: Baseline and Week 2
| Intervention | Counts (Mean) |
|---|---|
| Armodafinil 50 mg/Day | -11.3 |
| Armodafinil 100 mg/Day | -6.6 |
| Armodafinil 200 mg/Day | -6.6 |
| Placebo | -0.3 |
An actigraphy device was worn by each patient starting with the initial screening. The device continuously measured movement, allowing for an evaluation of spontaneous motor activity. Data from the actigraphy device were downloaded at each visit. The data presented here is the change from baseline to Week 2 in total activity. (NCT00487942)
Timeframe: Baseline and Week 2
| Intervention | Counts (Mean) |
|---|---|
| Armodafinil 50 mg/Day | 2346.8 |
| Armodafinil 100 mg/Day | -32082.8 |
| Armodafinil 200 mg/Day | 3103.1 |
| Placebo | 30660.0 |
An actigraphy device was worn by each patient starting with the initial screening. The device continuously measured movement, allowing for an evaluation of spontaneous motor activity. Data from the actigraphy device were downloaded at each visit. The data presented here is the change from baseline to Week 2 in total activity. (NCT00487942)
Timeframe: Baseline and Week 2
| Intervention | Counts (Mean) |
|---|---|
| Armodafinil 50 mg/Day | -3534.2 |
| Armodafinil 100 mg/Day | 27543.3 |
| Armodafinil 200 mg/Day | 7937.0 |
| Placebo | 27759.5 |
The Modified Simpson Angus Scale is a clinician-rated scale to assess the presence and severity of extrapyramidal symptoms associated study drug treatment. This is a 10-item scale that focuses on rigidity. The items are rated using a 5-point (0 - 4) scale. The total score ranges between 0 and 40. The data presented here represents the change from Baseline to Week 2. (NCT00487942)
Timeframe: Baseline and 2 weeks following the start of study drug administration
| Intervention | Units on a scale (Mean) |
|---|---|
| Armodafinil 50 mg/Day | 0.1 |
| Armodafinil 100 mg/Day | -0.4 |
| Armodafinil 200 mg/Day | -0.3 |
| Placebo | 0.0 |
PANSS is a clinician-rated instrument that rates the severity of psychopathology in patients with schizophrenia. 7 items measure positive symptoms (eg. delusions, hallucinations), 7 items measure negative symptoms (eg. blunted affect, social withdrawal), 16 items form a General Psychopathology scale (eg. anxiety, motor retardation). Each item is scored on a 7-point severity scale: 1=absent, 2=minimal, 3=mild, 4=moderate, 5=moderate severe, 6=severe, 7=extreme. The Negative Scale score ranges from 7 to 49. The data here represents the change in Negative Rating Scale from Baseline to Week 2. (NCT00487942)
Timeframe: Baseline and 2 weeks following the start of study drug administration
| Intervention | Units on a scale (Mean) |
|---|---|
| Armodafinil 50 mg/Day | -0.1 |
| Armodafinil 100 mg/Day | -1.4 |
| Armodafinil 200 mg/Day | -2.3 |
| Placebo | -0.8 |
PANSS is a clinician-rated instrument that rates the severity of psychopathology in patients with schizophrenia. 7 items measure positive symptoms (eg. delusions, hallucinations), 7 items measure negative symptoms (eg. blunted affect, social withdrawal), 16 items form a General Psychopathology scale (eg. anxiety, motor retardation). Each item is scored on a 7-point severity scale: 1=absent, 2=minimal, 3=mild, 4=moderate, 5=moderate severe, 6=severe, 7=extreme. The Positive Scale score ranges from 7 to 49. The data here represents the change in Positive Rating Scale from Baseline to Week 2. (NCT00487942)
Timeframe: Baseline and 2 weeks following the start of study drug administration
| Intervention | Units on a scale (Mean) |
|---|---|
| Armodafinil 50 mg/Day | -0.3 |
| Armodafinil 100 mg/Day | -1.1 |
| Armodafinil 200 mg/Day | 0.4 |
| Placebo | -0.9 |
PANSS is a clinician-rated instrument that rates the severity of psychopathology in patients with schizophrenia. 7 items measure positive symptoms (eg. delusions, hallucinations), 7 items measure negative symptoms (eg. blunted affect, social withdrawal), 16 items form a General Psychopathology scale (eg. anxiety, motor retardation). Each item is scored on a 7-point severity scale: 1=absent, 2=minimal, 3=mild, 4=moderate, 5=moderate severe, 6=severe, 7=extreme. The Total score ranges from 7 to 210. The data here represents the change in Total score from Baseline to Week 2. (NCT00487942)
Timeframe: Baseline and 2 weeks following the start of study drug administration
| Intervention | Units on a scale (Mean) |
|---|---|
| Armodafinil 50 mg/Day | -2.1 |
| Armodafinil 100 mg/Day | -3.2 |
| Armodafinil 200 mg/Day | -3.0 |
| Placebo | -2.8 |
n The SCoRS is an 18-item interview based assessment covering all the cognitive domains in the MATRICS Consensus Cognitive Battery except social cognition. It is administered separately to the patient and an informant (family or friend) who are asked to rate the patient's level of difficulty in performing various cognitive functions on a 4-point scale (higher rating = greater impairment). They also complete a global assessment of cognitive function on a 1-10 scale. The interviewer factors in their own assessment on both the 18-items (Total Score) and the global assessment for the final score. (NCT00487942)
Timeframe: Baseline and 2 weeks following the start of study drug administration
| Intervention | Units on a scale (Mean) |
|---|---|
| Armodafinil 50 mg/Day | 0.0 |
| Armodafinil 100 mg/Day | -0.3 |
| Armodafinil 200 mg/Day | 0.6 |
| Placebo | -0.8 |
The SCoRS is an 18-item interview based assessment covering all the cognitive domains in the MATRICS Consensus Cognitive Battery except social cognition. It is administered separately to the patient and an informant (family or friend) who are asked to rate the patient's level of difficulty in performing various cognitive functions on a 4-point scale (higher rating = greater impairment). They also complete a global assessment of cognitive function on a 1-10 scale. The interviewer factors in their own assessment on both the 18-items (Total Score) and the global assessment for the final score. (NCT00487942)
Timeframe: Baseline and 2 weeks following the start of study drug administration
| Intervention | Units on a scale (Mean) |
|---|---|
| Armodafinil 50 mg/Day | -5.0 |
| Armodafinil 100 mg/Day | -3.0 |
| Armodafinil 200 mg/Day | -1.6 |
| Placebo | -3.3 |
The CDSS is a clinician-rated scale that assesses the level of depression in patients with schizophrenia. Each of the 9 items is scored on a 4-point scale (0=absent, 1=mild, 2=moderate, 3=severe). The total score range is 0 - 27. The data presented here represents the change from Baseline to Week 2 in the total score. (NCT00487942)
Timeframe: Baseline and 2 weeks following the start of study drug administration
| Intervention | Units on a scale (Mean) |
|---|---|
| Armodafinil 50 mg/Day | 0.7 |
| Armodafinil 100 mg/Day | -1.1 |
| Armodafinil 200 mg/Day | -0.8 |
| Placebo | 0.4 |
An actigraphy device was worn by each patient starting with the initial screening. The device continuously measured movement, allowing for an evaluation of spontaneous motor activity. Data from the actigraphy device were downloaded at each visit. The data presented here is the change from baseline to Week 3 in total activity. (NCT00487942)
Timeframe: Baseline and Week 3
| Intervention | Counts (Mean) |
|---|---|
| Armodafinil 50 mg/Day | 40120.5 |
| Armodafinil 100 mg/Day | 23748.0 |
| Armodafinil 200 mg/Day | 61304.7 |
| Placebo | -41751.7 |
An actigraphy device was worn by each patient starting with the initial screening. The device continuously measured movement, allowing for an evaluation of spontaneous motor activity. Data from the actigraphy device were downloaded at each visit. The data presented here is the change from baseline in average activity per epoch (counts/epoch) to Week 3. (NCT00487942)
Timeframe: Baseline and Week 3
| Intervention | Counts (Mean) |
|---|---|
| Armodafinil 50 mg/Day | 1.5 |
| Armodafinil 100 mg/Day | 7.2 |
| Armodafinil 200 mg/Day | 9.9 |
| Placebo | -1.6 |
An actigraphy device was worn by each patient starting with the initial screening. The device continuously measured movement, allowing for an evaluation of spontaneous motor activity. Data from the actigraphy device were downloaded at each visit. The data presented here is the change from baseline to Week 3 in maximum activity. (NCT00487942)
Timeframe: Baseline and Week 3
| Intervention | Counts (Mean) |
|---|---|
| Armodafinil 50 mg/Day | 1420.4 |
| Armodafinil 100 mg/Day | 1522.5 |
| Armodafinil 200 mg/Day | 1469.2 |
| Placebo | 1505.1 |
An actigraphy device was worn by each patient starting with the initial screening. The device continuously measured movement, allowing for an evaluation of spontaneous motor activity. Data from the actigraphy device were downloaded at each visit. The data presented here is the change from baseline to Week 3 in standard deviation of activity (counts/epoch). (NCT00487942)
Timeframe: Baseline and Week 3
| Intervention | Counts (Mean) |
|---|---|
| Armodafinil 50 mg/Day | 5.2 |
| Armodafinil 100 mg/Day | -6.6 |
| Armodafinil 200 mg/Day | 15.2 |
| Placebo | 1.1 |
An actigraphy device was worn by each patient starting with the initial screening. The device continuously measured movement, allowing for an evaluation of spontaneous motor activity. Data from the actigraphy device were downloaded at each visit. The data presented here is the change from baseline to Week 3 in total activity. (NCT00487942)
Timeframe: Baseline and Week 3
| Intervention | Counts (Mean) |
|---|---|
| Armodafinil 50 mg/Day | 39831.8 |
| Armodafinil 100 mg/Day | 16850.4 |
| Armodafinil 200 mg/Day | 56889.1 |
| Placebo | 29067.5 |
An actigraphy device was worn by each patient starting with the initial screening. The device continuously measured movement, allowing for an evaluation of spontaneous motor activity. Data from the actigraphy device were downloaded at each visit. The data presented here is the change from baseline to Week 3 in total activity. (NCT00487942)
Timeframe: Baseline and Week 3
| Intervention | Counts (Mean) |
|---|---|
| Armodafinil 50 mg/Day | 89886.7 |
| Armodafinil 100 mg/Day | 91057.2 |
| Armodafinil 200 mg/Day | 126496.5 |
| Placebo | 60259.0 |
ESS is a self-administered subjective measure of daytime sleepiness, based on responses to questions referring to 8 everyday situations (eg. sitting and reading, talking to someone) and reflects a patient's propensity to fall asleep in those situations. Score for the ESS range from 0 to 24 with higher scores indicating greater daytime sleepiness. Data here represents the change from Baseline to Week 4 in the ESS total score. (NCT00487942)
Timeframe: Baseline and 4 weeks following the start of study drug administration
| Intervention | Units on a scale (Mean) |
|---|---|
| Armodafinil 50 mg/Day | -2.0 |
| Armodafinil 100 mg/Day | -0.5 |
| Armodafinil 200 mg/Day | 1.0 |
| Placebo | -1.7 |
The MATRICS Consensus Cognitive Battery is an instrument that contains 10 tests to measure cognitive performance in 7 cognitive domains: speed processing, attention/vigilance, working memory, verbal learning, visual learning, reasoning and problem solving, and social cognition. The composite score combines the individual scores of the 10 tests and scores them on a normative scale to derive a T-score, where the mean is 50 and a standard deviation is 10 for the composite. The data here represent the mean change in composite T-score from baseline to 4 weeks. (NCT00487942)
Timeframe: Baseline and 4 weeks
| Intervention | Units on a scale (Mean) |
|---|---|
| Armodafinil 50 mg/Day | 2.2 |
| Armodafinil 100 mg/Day | 3.9 |
| Armodafinil 200 mg/Day | 2.9 |
| Placebo | 2.1 |
SANS is a clinician-rated instrument that rates the severity of negative symptoms of schizophrenia. It contains 25 items in 5 domains: affective flattening/blunting, alogia, avolition-apathy, anhedonia-asociality, attentional impairment. Items in a domain assess symptoms and a global item assesses the overall severity of the domain. Each item is scored on a 6-point severity scale(0=Not at all, 1=questionable decrease, 2=mild, 3=moderate, 4=marked, 5=severe). The total scale ranges from 0-125. Data presented here represents change in total score from Baseline to Week 4. (NCT00487942)
Timeframe: Baseline and 4 weeks following the start of study drug administration
| Intervention | Units on a scale (Mean) |
|---|---|
| Armodafinil 50 mg/Day | -5.3 |
| Armodafinil 100 mg/Day | -5.6 |
| Armodafinil 200 mg/Day | -7.4 |
| Placebo | -6.3 |
The BARS is a 4-item clinician-rated scale to measure the presence and severity of drug-induced akathisia. Items related to the assessment of objective akathisia, subjective awareness of restlessness, and distress related to restlessness are rated using various 4-point (0 - 3) scales. A global assessment of akathisia is rated using a 6-point (0=Absent, 1=Questionable akathisia, 2=Mild akathisia, 3=Moderate akathisia, 4=Marked akathisia, 5=Severe akathisia) scale. The total score range is from 0 to 14 with a higher score indicating more severe akathisia. (NCT00487942)
Timeframe: Baseline and 4 weeks following the start of study drug administration
| Intervention | Units on a scale (Mean) |
|---|---|
| Armodafinil 50 mg/Day | -0.1 |
| Armodafinil 100 mg/Day | -0.2 |
| Armodafinil 200 mg/Day | -0.2 |
| Placebo | -0.1 |
An actigraphy device was worn by each patient starting with the initial screening. The device continuously measured movement, allowing for an evaluation of spontaneous motor activity. Data from the actigraphy device were downloaded at each visit. The data presented here is the change from baseline to Week 4 in total activity. (NCT00487942)
Timeframe: Baseline and Week 4
| Intervention | Counts (Mean) |
|---|---|
| Armodafinil 50 mg/Day | 7898.0 |
| Armodafinil 100 mg/Day | -10300.1 |
| Armodafinil 200 mg/Day | 123442.9 |
| Placebo | -240840 |
An actigraphy device was worn by each patient starting with the initial screening. The device continuously measured movement, allowing for an evaluation of spontaneous motor activity. Data from the actigraphy device were downloaded at each visit. The data presented here is the change from baseline in average activity per epoch (counts/epoch) to Week 4. (NCT00487942)
Timeframe: Baseline and Week 4
| Intervention | Counts (Mean) |
|---|---|
| Armodafinil 50 mg/Day | -15.4 |
| Armodafinil 100 mg/Day | 9.0 |
| Armodafinil 200 mg/Day | -0.4 |
| Placebo | -18.7 |
An actigraphy device was worn by each patient starting with the initial screening. The device continuously measured movement, allowing for an evaluation of spontaneous motor activity. Data from the actigraphy device were downloaded at each visit. The data presented here is the change from baseline to week 4 in maximum activity. (NCT00487942)
Timeframe: Baseline and Week 4
| Intervention | Counts (Mean) |
|---|---|
| Armodafinil 50 mg/Day | -173.5 |
| Armodafinil 100 mg/Day | -61.4 |
| Armodafinil 200 mg/Day | 57.5 |
| Placebo | -60.4 |
An actigraphy device was worn by each patient starting with the initial screening. The device continuously measured movement, allowing for an evaluation of spontaneous motor activity. Data from the actigraphy device were downloaded at each visit. The data presented here is the change from baseline to week 4 in standard deviation of activity (counts/epoch). (NCT00487942)
Timeframe: Baseline and Week 4
| Intervention | Counts (Mean) |
|---|---|
| Armodafinil 50 mg/Day | -7.9 |
| Armodafinil 100 mg/Day | 6.3 |
| Armodafinil 200 mg/Day | 7.4 |
| Placebo | -7.6 |
An actigraphy device was worn by each patient starting with the initial screening. The device continuously measured movement, allowing for an evaluation of spontaneous motor activity. Data from the actigraphy device were downloaded at each visit. The data presented here is the change from baseline to Week 4 in total activity. (NCT00487942)
Timeframe: Baseline and Week 4
| Intervention | Counts (Mean) |
|---|---|
| Armodafinil 50 mg/Day | 1341.8 |
| Armodafinil 100 mg/Day | 12620.9 |
| Armodafinil 200 mg/Day | 55151.0 |
| Placebo | -24323.9 |
An actigraphy device was worn by each patient starting with the initial screening. The device continuously measured movement, allowing for an evaluation of spontaneous motor activity. Data from the actigraphy device were downloaded at each visit. The data presented here is the change from baseline to week 4 in total activity. (NCT00487942)
Timeframe: Baseline and Week 4
| Intervention | Counts (Mean) |
|---|---|
| Armodafinil 50 mg/Day | -12493.6 |
| Armodafinil 100 mg/Day | -6742.8 |
| Armodafinil 200 mg/Day | 39458.0 |
| Placebo | 1744.3 |
The Modified Simpson Angus Scale is a clinician-rated scale to assess the presence and severity of extrapyramidal symptoms associated study drug treatment. This is a 10-item scale that focuses on rigidity. The items are rated using a 5-point (0 - 4) scale. The total score ranges between 0 and 40. The data presented here represents the change from Baseline to Week 4. (NCT00487942)
Timeframe: Baseline and 4 weeks following the start of study drug administration
| Intervention | Units on a scale (Mean) |
|---|---|
| Armodafinil 50 mg/Day | -0.1 |
| Armodafinil 100 mg/Day | -0.1 |
| Armodafinil 200 mg/Day | -0.2 |
| Placebo | 0.2 |
PANSS is a clinician-rated instrument that rates the severity of psychopathology in patients with schizophrenia. 7 items measure positive symptoms (eg. delusions, hallucinations), 7 items measure negative symptoms (eg. blunted affect, social withdrawal), 16 items form a General Psychopathology scale (eg. anxiety, motor retardation). Each item is scored on a 7-point severity scale: 1=absent, 2=minimal, 3=mild, 4=moderate, 5=moderate severe, 6=severe, 7=extreme. The Negative Scale score ranges from 7 to 49. The data here represents the change in Negative Rating Scale from Baseline to Week 4. (NCT00487942)
Timeframe: Baseline and 4 weeks following the start of study drug administration
| Intervention | Units on a scale (Mean) |
|---|---|
| Armodafinil 50 mg/Day | -0.1 |
| Armodafinil 100 mg/Day | -1.3 |
| Armodafinil 200 mg/Day | -3.4 |
| Placebo | 0.0 |
PANSS is a clinician-rated instrument that rates the severity of psychopathology in patients with schizophrenia. 7 items measure positive symptoms (eg. delusions, hallucinations), 7 items measure negative symptoms (eg. blunted affect, social withdrawal), 16 items form a General Psychopathology scale (eg. anxiety, motor retardation). Each item is scored on a 7-point severity scale: 1=absent, 2=minimal, 3=mild, 4=moderate, 5=moderate severe, 6=severe, 7=extreme. The Positive Scale score ranges from 7 to 49. The data here represents the change in Positive Rating Scale from Baseline to Week 4. (NCT00487942)
Timeframe: Baseline and 4 weeks following the start of study drug administration
| Intervention | Units on a scale (Mean) |
|---|---|
| Armodafinil 50 mg/Day | -0.7 |
| Armodafinil 100 mg/Day | -0.8 |
| Armodafinil 200 mg/Day | -0.6 |
| Placebo | -1.0 |
PANSS is a clinician-rated instrument that rates the severity of psychopathology in patients with schizophrenia. 7 items measure positive symptoms (eg. delusions, hallucinations), 7 items measure negative symptoms (eg. blunted affect, social withdrawal), 16 items form a General Psychopathology scale (eg. anxiety, motor retardation). Each item is scored on a 7-point severity scale: 1=absent, 2=minimal, 3=mild, 4=moderate, 5=moderate severe, 6=severe, 7=extreme. The Total score ranges from 7 to 210. The data here represents the change in Total score from Baseline to Week 4. (NCT00487942)
Timeframe: Baseline and 4 weeks following the start of study drug administration
| Intervention | Units on a scale (Mean) |
|---|---|
| Armodafinil 50 mg/Day | -2.1 |
| Armodafinil 100 mg/Day | -3.1 |
| Armodafinil 200 mg/Day | -6.3 |
| Placebo | -2.1 |
The SCoRS is an 18-item interview based assessment covering all the cognitive domains in the MATRICS Consensus Cognitive Battery except social cognition. It is administered separately to the patient and an informant (family or friend) who are asked to rate the patient's level of difficulty in performing various cognitive functions on a 4-point scale (higher rating = greater impairment). They also complete a global assessment of cognitive function on a 1-10 scale. The interviewer factors in their own assessment on both the 18-items (Total Score) and the global assessment for the final score. (NCT00487942)
Timeframe: Baseline and 4 weeks following the start of study drug administration
| Intervention | Units on a scale (Mean) |
|---|---|
| Armodafinil 50 mg/Day | -0.1 |
| Armodafinil 100 mg/Day | -0.4 |
| Armodafinil 200 mg/Day | -0.3 |
| Placebo | -0.5 |
The SCoRS is an 18-item interview based assessment covering all the cognitive domains in the MATRICS Consensus Cognitive Battery except social cognition. It is administered separately to the patient and an informant (family or friend) who are asked to rate the patient's level of difficulty in performing various cognitive functions on a 4-point scale (higher rating = greater impairment). They also complete a global assessment of cognitive function on a 1-10 scale. The interviewer factors in their own assessment on both the 18-items (Total Score) and the global assessment for the final score. (NCT00487942)
Timeframe: Baseline and 4 weeks following the start of study drug administration
| Intervention | Units on a scale (Mean) |
|---|---|
| Armodafinil 50 mg/Day | -3.8 |
| Armodafinil 100 mg/Day | -1.8 |
| Armodafinil 200 mg/Day | -4.6 |
| Placebo | -2.6 |
The CDSS is a clinician-rated scale that assesses the level of depression in patients with schizophrenia. Each of the 9 items is scored on a 4-point scale (0=absent, 1=mild, 2=moderate, 3=severe). The total score range is 0 - 27. The data presented here represents the change from Baseline to Week 4 in the total score. (NCT00487942)
Timeframe: Baseline and 4 weeks following the start of study drug administration
| Intervention | Units on a scale (Mean) |
|---|---|
| Armodafinil 50 mg/Day | 0.0 |
| Armodafinil 100 mg/Day | -0.6 |
| Armodafinil 200 mg/Day | 0.3 |
| Placebo | 0.2 |
SANS is a clinician-rated instrument that rates the severity of negative symptoms of schizophrenia. It contains 25 items in 5 domains: affective flattening/blunting, alogia, avolition-apathy, anhedonia-asociality, attentional impairment. Items in a domain assess symptoms and a global item assesses the overall severity of the domain. Each item is scored on a 6-point severity scale(0=Not at all, 1=questionable decrease, 2=mild, 3=moderate, 4=marked, 5=severe). The total scale ranges from 0-125. Data presented here represents change in total score from Baseline to Endpoint. (NCT00487942)
Timeframe: Baseline and 4 weeks (or last observation after Baseline)
| Intervention | Units on a scale (Mean) |
|---|---|
| Armodafinil 50 mg/Day | -5.6 |
| Armodafinil 100 mg/Day | -3.0 |
| Armodafinil 200 mg/Day | -7.4 |
| Placebo | -6.1 |
The MATRICS Consensus Cognitive Battery is an instrument containing 10 tests to measure cognitive performance in 7 cognitive domains: speed processing, attention/vigilance, working memory, verbal learning, visual learning, reasoning and problem solving, and social cognition. The Domain score combines the individual test scores of the Domain and scores them on a normative scale to derive a T-score, where the mean is 50 and a standard deviation is 10 for the composite. The data here represent the mean change in Attention/Vigilance Domain T-score from baseline to last observation after baseline. (NCT00487942)
Timeframe: Baseline and 4 weeks (or last observation after baseline)
| Intervention | Units on a scale (Mean) |
|---|---|
| Armodafinil 50 mg/Day | 0.4 |
| Armodafinil 100 mg/Day | 3.7 |
| Armodafinil 200 mg/Day | 1.8 |
| Placebo | 3.0 |
The MATRICS Consensus Cognitive Battery is an instrument that contains 10 tests to measure cognitive performance in 7 cognitive domains: speed processing, attention/vigilance, working memory, verbal learning, visual learning, reasoning and problem solving, and social cognition. The BASC SC Test is a component of the Speed of Processing Domain scored on a normative scale to derive a T-score, (mean is 50 and standard deviation is 10). The data here represent the mean change in BASC SC Test T-score from baseline to last observation after baseline. (NCT00487942)
Timeframe: Baseline and 4 weeks (or last observation after Baseline)
| Intervention | Units on a scale (Mean) |
|---|---|
| Armodafinil 50 mg/Day | 0.6 |
| Armodafinil 100 mg/Day | -0.4 |
| Armodafinil 200 mg/Day | 2.4 |
| Placebo | 4.0 |
The MATRICS Consensus Cognitive Battery is an instrument that contains 10 tests to measure cognitive performance in 7 cognitive domains: speed processing, attention/vigilance, working memory, verbal learning, visual learning, reasoning and problem solving, and social cognition. The Fluency Test is a component of the Speed of Processing Domain scored on a normative scale to derive a T-score, (mean is 50 and standard deviation is 10). The data here represent the mean change in Fluency Test T-score from baseline to last observation after baseline. (NCT00487942)
Timeframe: Baseline and 4 weeks (or last observation after Baseline)
| Intervention | Units on a scale (Mean) |
|---|---|
| Armodafinil 50 mg/Day | 2.2 |
| Armodafinil 100 mg/Day | 0.8 |
| Armodafinil 200 mg/Day | -0.5 |
| Placebo | -1.4 |
The MATRICS Consensus Cognitive Battery is an instrument that contains 10 tests to measure cognitive performance in 7 cognitive domains: speed processing, attention/vigilance, working memory, verbal learning, visual learning, reasoning and problem solving, and social cognition. The LNS is a component of the Working Memory Domain scored on a normative scale to derive a T-score, (mean is 50 and standard deviation is 10). The data here represent the mean change in LNS T-score from baseline to last observation after baseline. (NCT00487942)
Timeframe: Baseline and 4 weeks (or last observation after Baseline)
| Intervention | Units on a scale (Mean) |
|---|---|
| Armodafinil 50 mg/Day | 3.1 |
| Armodafinil 100 mg/Day | 2.1 |
| Armodafinil 200 mg/Day | 3.1 |
| Placebo | 4.5 |
The Modified Simpson Angus Scale is a clinician-rated scale to assess the presence and severity of extrapyramidal symptoms associated study drug treatment. This is a 10-item scale that focuses on rigidity. The items are rated using a 5-point (0 - 4) scale. The total score ranges between 0 and 40. The data presented here represents the change from Baseline to Week 4 or the last observation following baseline. (NCT00487942)
Timeframe: Baseline and 4 weeks (or last observation after Baseline)
| Intervention | Units on a scale (Mean) |
|---|---|
| Armodafinil 50 mg/Day | 0.1 |
| Armodafinil 100 mg/Day | -0.1 |
| Armodafinil 200 mg/Day | -0.3 |
| Placebo | 0.3 |
PANSS is a clinician-rated instrument that rates the severity of psychopathology in patients with schizophrenia. 7 items measure positive symptoms (eg. delusions, hallucinations), 7 items measure negative symptoms (eg. blunted affect, social withdrawal), 16 items form a General Psychopathology scale (eg. anxiety, motor retardation). Each item is scored on a 7-point severity scale: 1=absent, 2=minimal, 3=mild, 4=moderate, 5=moderate severe, 6=severe, 7=extreme. The Negative Scale score ranges from 7 to 49. The data here represents the change in Negative Rating Scale from Baseline to Endpoint. (NCT00487942)
Timeframe: Baseline and 4 weeks (or last observation after Baseline)
| Intervention | Units on a scale (Mean) |
|---|---|
| Armodafinil 50 mg/Day | -0.3 |
| Armodafinil 100 mg/Day | -0.3 |
| Armodafinil 200 mg/Day | -3.4 |
| Placebo | 0.1 |
PANSS is a clinician-rated instrument that rates the severity of psychopathology in patients with schizophrenia. 7 items measure positive symptoms (eg. delusions, hallucinations), 7 items measure negative symptoms (eg. blunted affect, social withdrawal), 16 items form a General Psychopathology scale (eg. anxiety, motor retardation). Each item is scored on a 7-point severity scale: 1=absent, 2=minimal, 3=mild, 4=moderate, 5=moderate severe, 6=severe, 7=extreme. The Positive Scale score ranges from 7 to 49. The data here represents the change in Positive Rating Scale from Baseline to Endpoint. (NCT00487942)
Timeframe: Baseline and 4 weeks (or last observation after Baseline)
| Intervention | Units on a scale (Mean) |
|---|---|
| Armodafinil 50 mg/Day | -0.7 |
| Armodafinil 100 mg/Day | 0.1 |
| Armodafinil 200 mg/Day | -0.4 |
| Placebo | -0.9 |
The MATRICS Consensus Cognitive Battery is an instrument containing 10 tests to measure cognitive performance in 7 cognitive domains: speed processing, attention/vigilance, working memory, verbal learning, visual learning, reasoning and problem solving, and social cognition. The Domain score combines the individual test scores of the Domain and scores them on a normative scale to derive a T-score, (mean is 50 and standard deviation is 10) for the composite. The data here represent the mean change in Reasoning and Problem Solving Domain T-score from baseline to last observation after baseline. (NCT00487942)
Timeframe: Baseline and 4 weeks (or last observation after Baseline)
| Intervention | Units on a scale (Mean) |
|---|---|
| Armodafinil 50 mg/Day | 1.6 |
| Armodafinil 100 mg/Day | -0.4 |
| Armodafinil 200 mg/Day | -0.3 |
| Placebo | -0.2 |
The SCoRS is an 18-item interview based assessment covering all the cognitive domains in the MATRICS Consensus Cognitive Battery except social cognition. It is administered separately to the patient and an informant (family or friend) who are asked to rate the patient's level of difficulty in performing various cognitive functions on a 4-point scale (higher rating = greater impairment). They also complete a global assessment of cognitive function on a 1-10 scale. The interviewer factors in their own assessment on both the 18-items (Total Score) and the global assessment for the final score. (NCT00487942)
Timeframe: Baseline and 4 weeks (or last observation after Baseline)
| Intervention | Units on a scale (Mean) |
|---|---|
| Armodafinil 50 mg/Day | 0.3 |
| Armodafinil 100 mg/Day | -0.2 |
| Armodafinil 200 mg/Day | -0.3 |
| Placebo | -0.4 |
The MATRICS Consensus Cognitive Battery is an instrument that contains 10 tests to measure cognitive performance in 7 cognitive domains: speed processing, attention/vigilance, working memory, verbal learning, visual learning, reasoning and problem solving, and social cognition. The Domain score combines the individual test scores of the Domain and scores them on a normative scale to derive a T-score, (mean is 50 and standard deviation is 10) for the composite. The data here represent the mean change in Social Cognition Domain T-score from baseline to last observation after baseline. (NCT00487942)
Timeframe: Baseline and 4 weeks (or last observation after Baseline)
| Intervention | Units on a scale (Mean) |
|---|---|
| Armodafinil 50 mg/Day | -3.1 |
| Armodafinil 100 mg/Day | -1.3 |
| Armodafinil 200 mg/Day | 3.6 |
| Placebo | 3.8 |
The MATRICS Consensus Cognitive Battery is an instrument that contains 10 tests to measure cognitive performance in 7 cognitive domains: speed processing, attention/vigilance, working memory, verbal learning, visual learning, reasoning and problem solving, and social cognition. The Domain score combines the individual test scores of the Domain and scores them on a normative scale to derive a T-score, where the mean is 50 and a standard deviation is 10 for the composite. The data here represent the mean change in Processing Speed Domain T-score from baseline to last observation after baseline. (NCT00487942)
Timeframe: Baseline 4 weeks (or last observation after baseline)
| Intervention | Units on a scale (Mean) |
|---|---|
| Armodafinil 50 mg/Day | 3.0 |
| Armodafinil 100 mg/Day | 0.0 |
| Armodafinil 200 mg/Day | 5.0 |
| Placebo | 0.9 |
The MATRICS Consensus Cognitive Battery is an instrument that contains 10 tests to measure cognitive performance in 7 cognitive domains: speed processing, attention/vigilance, working memory, verbal learning, visual learning, reasoning and problem solving, and social cognition. The Trail Making Test is a component of the Speed of Processing Domain scored on a normative scale to derive a T-score, (mean is 50 and standard deviation is 10). The data here represent the mean change in Trail Making Test T-score from baseline to last observation after baseline. (NCT00487942)
Timeframe: Baseline and 4 weeks (or last observation after Baseline)
| Intervention | Units on a scale (Mean) |
|---|---|
| Armodafinil 50 mg/Day | 4.2 |
| Armodafinil 100 mg/Day | -0.2 |
| Armodafinil 200 mg/Day | 9.2 |
| Placebo | -1.0 |
Trail B is an instrument designed to assess set shifting. The patient was given a paper with numbers and letters on it and asked to connect them in an alternating manner (eg. 1-A-2-B-3C). The time required for the patient to complete the test was recorded. The change from Baseline to last observation following Baseline in the time necessary to complete the test is presented here. (NCT00487942)
Timeframe: Baseline and 4 weeks (or last observation after Baseline)
| Intervention | Minutes (Mean) |
|---|---|
| Armodafinil 50 mg/Day | -8.7 |
| Armodafinil 100 mg/Day | 17.5 |
| Armodafinil 200 mg/Day | -20.8 |
| Placebo | -27.6 |
The MATRICS Consensus Cognitive Battery is an instrument that contains 10 tests to measure cognitive performance in 7 cognitive domains: speed processing, attention/vigilance, working memory, verbal learning, visual learning, reasoning and problem solving, and social cognition. The Domain score combines the individual test scores of the Domain and scores them on a normative scale to derive a T-score, where the mean is 50 and a standard deviation is 10 for the composite. The data here represent the mean change in Verbal Learning Domain T-score from baseline to last observation after baseline. (NCT00487942)
Timeframe: Baseline and 4 weeks (or last observation after Baseline)
| Intervention | Units on a scale (Mean) |
|---|---|
| Armodafinil 50 mg/Day | -1.2 |
| Armodafinil 100 mg/Day | -0.8 |
| Armodafinil 200 mg/Day | 0.8 |
| Placebo | -2.2 |
The MATRICS Consensus Cognitive Battery is an instrument that contains 10 tests to measure cognitive performance in 7 cognitive domains: speed processing, attention/vigilance, working memory, verbal learning, visual learning, reasoning and problem solving, and social cognition. The Domain score combines the individual test scores of the Domain and scores them on a normative scale to derive a T-score, where the mean is 50 and a standard deviation is 10 for the composite. The data here represent the mean change in Visual Learning Domain T-score from baseline to last observation after baseline. (NCT00487942)
Timeframe: Baseline and 4 weeks (or last observation after Baseline)
| Intervention | Units on a scale (Mean) |
|---|---|
| Armodafinil 50 mg/Day | 4.3 |
| Armodafinil 100 mg/Day | 3.9 |
| Armodafinil 200 mg/Day | 1.3 |
| Placebo | 0.2 |
The MATRICS Consensus Cognitive Battery is an instrument that contains 10 tests to measure cognitive performance in 7 cognitive domains: speed processing, attention/vigilance, working memory, verbal learning, visual learning, reasoning and problem solving, and social cognition. The WMS-III SS is a component of the Working Memory Domain scored on a normative scale to derive a T-score, (mean is 50 and standard deviation is 10). The data here represent the mean change in WMS-III SS T-score from baseline to last observation after baseline. (NCT00487942)
Timeframe: Baseline and 4 weeks (or last observation after Baseline)
| Intervention | Units on a scale (Mean) |
|---|---|
| Armodafinil 50 mg/Day | 0.7 |
| Armodafinil 100 mg/Day | 4.7 |
| Armodafinil 200 mg/Day | 2.9 |
| Placebo | 2.5 |
"WCST is an instrument administered electronically to assess abstract reasoning and ability to alter problem solving strategies. Patients are given 64 response cards and 4 stimulus cards and asked to match each stimulus card to 1 pile of response cards. The patient is not told how to match the cards, only right or wrong to each placement. Examiner may change matching rules (sorting categories) during the test at which time the subject must alter their sorting category. The change from baseline in number of sorting categories achieved was assessed." (NCT00487942)
Timeframe: Baseline and 4 weeks (or last observation after Baseline)
| Intervention | Categories Completed (Mean) |
|---|---|
| Armodafinil 50 mg/Day | 0.0 |
| Armodafinil 100 mg/Day | 0.5 |
| Armodafinil 200 mg/Day | -0.3 |
| Placebo | 0.2 |
"WCST is an instrument administered electronically to assess abstract reasoning and ability to alter problem solving strategies. Patients are given 64 response cards and 4 stimulus cards and asked to match each stimulus card to 1 pile of response cards. The patient is not told how to match the cards, only right or wrong to each placement. Examiner may change matching rules (sorting categories) during the test at which time the subject must alter their sorting category. The change from baseline in number of consecutive responses on the final category was assessed." (NCT00487942)
Timeframe: Baseline and 4 weeks (or last observation after Baseline)
| Intervention | Responses (Mean) |
|---|---|
| Armodafinil 50 mg/Day | -1.6 |
| Armodafinil 100 mg/Day | -0.5 |
| Armodafinil 200 mg/Day | 0.3 |
| Placebo | 0.7 |
"WCST is an instrument administered electronically to assess abstract reasoning and ability to alter problem solving strategies. Patients are given 64 response cards and 4 stimulus cards and asked to match each stimulus card to 1 pile of response cards. The patient is not told how to match the cards, only right or wrong to each placement. Examiner may change matching rules during the test. Perseveration errors occur when subject repeats the same error no matter how many times they are told the placement is wrong. The change from baseline in number of perseveration errors was assessed." (NCT00487942)
Timeframe: 4 weeks (or last observation after baseline)
| Intervention | Errors (Mean) |
|---|---|
| Armodafinil 50 mg/Day | 1.6 |
| Armodafinil 100 mg/Day | -8.0 |
| Armodafinil 200 mg/Day | -2.2 |
| Placebo | -1.9 |
The MATRICS Consensus Cognitive Battery is an instrument that contains 10 tests to measure cognitive performance in 7 cognitive domains: speed processing, attention/vigilance, working memory, verbal learning, visual learning, reasoning and problem solving, and social cognition. The Domain score combines the individual test scores of the Domain and scores them on a normative scale to derive a T-score, where the mean is 50 and a standard deviation is 10 for the composite. The data here represent the mean change in Working Memory Domain T-score from baseline to last observation after baseline. (NCT00487942)
Timeframe: Baseline and 4 weeks (or last observation after Baseline)
| Intervention | Units on a scale (Mean) |
|---|---|
| Armodafinil 50 mg/Day | 2.3 |
| Armodafinil 100 mg/Day | 4.3 |
| Armodafinil 200 mg/Day | 3.5 |
| Placebo | 4.4 |
The CDSS is a clinician-rated scale that assesses the level of depression in patients with schizophrenia. Each of the 9 items is scored on a 4-point scale (0=absent, 1=mild, 2=moderate, 3=severe). The total score range is 0 - 27. The data presented here represents the change from Baseline to Week 4 or the last observation following baseline in the total score. (NCT00487942)
Timeframe: Baseline and 4 weeks (or last observation after Baseline)
| Intervention | Units on a scale (Mean) |
|---|---|
| Armodafinil 50 mg/Day | 0.2 |
| Armodafinil 100 mg/Day | -0.4 |
| Armodafinil 200 mg/Day | 0.3 |
| Placebo | 0.1 |
ESS is a self-administered subjective measure of daytime sleepiness, based on responses to questions referring to 8 everyday situations (eg. sitting and reading, talking to someone) and reflects a patient's propensity to fall asleep in those situations. Score for the ESS range from 0 to 24 with higher scores indicating greater daytime sleepiness. Data here represents the change from Baseline to Endpoint (Week 4 or last observation following baseline) in the ESS total score. (NCT00487942)
Timeframe: Baseline and 4 weeks (or last observation after Baseline)
| Intervention | Units on a scale (Mean) |
|---|---|
| Armodafinil 50 mg/Day | -2.1 |
| Armodafinil 100 mg/Day | -0.6 |
| Armodafinil 200 mg/Day | 1.0 |
| Placebo | -0.5 |
The BARS is a 4-item clinician-rated scale to measure the presence and severity of drug-induced akathisia. Items related to the assessment of objective akathisia, subjective awareness of restlessness, and distress related to restlessness are rated using various 4-point (0 - 3) scales. A global assessment of akathisia is rated using a 6-point (0=Absent, 1=Questionable akathisia, 2=Mild akathisia, 3=Moderate akathisia, 4=Marked akathisia, 5=Severe akathisia) scale. The total score range is from 0 to 14 with a higher score indicating more severe akathisia. (NCT00487942)
Timeframe: Baseline and 4 weeks (or last observation after Baseline)
| Intervention | Units on a scale (Mean) |
|---|---|
| Armodafinil 50 mg/Day | -0.3 |
| Armodafinil 100 mg/Day | -0.1 |
| Armodafinil 200 mg/Day | -0.1 |
| Placebo | -0.1 |
PANSS is a clinician-rated instrument that rates the severity of psychopathology in patients with schizophrenia. 7 items measure positive symptoms (eg. delusions, hallucinations), 7 items measure negative symptoms (eg. blunted affect, social withdrawal), 16 items form a General Psychopathology scale (eg. anxiety, motor retardation). Each item is scored on a 7-point severity scale: 1=absent, 2=minimal, 3=mild, 4=moderate, 5=moderate severe, 6=severe, 7=extreme. The Total score ranges from 7 to 210. The data here represents the change in Total score from Baseline to Endpoint. (NCT00487942)
Timeframe: Baseline and 4 weeks (or last observation after Baseline)
| Intervention | Units on a scale (Mean) |
|---|---|
| Armodafinil 50 mg/Day | -2.5 |
| Armodafinil 100 mg/Day | -0.9 |
| Armodafinil 200 mg/Day | -6.3 |
| Placebo | -1.7 |
The MATRICS Consensus Cognitive Battery is an instrument that contains 10 tests to measure cognitive performance in 7 cognitive domains: speed processing, attention/vigilance, working memory, verbal learning, visual learning, reasoning and problem solving, and social cognition. The composite score combines the individual scores of the 10 tests and scores them on a normative scale to derive a T-score, where the mean is 50 and a standard deviation is 10 for the composite. The data here represents the change from baseline to last observation after baseline in Composite T-Score. (NCT00487942)
Timeframe: Baseline and 4 weeks (or last observation after Baseline)
| Intervention | Units on a scale (Mean) |
|---|---|
| Armodafinil 50 mg/Day | 1.9 |
| Armodafinil 100 mg/Day | 2.8 |
| Armodafinil 200 mg/Day | 2.9 |
| Placebo | 2.2 |
The CGI-S is a standardized, clinician-rated assessment to rate the severity of illness of the patient. The clinician assessed the severity of illness using the following categories: 1 = normal, 2 = borderline ill, 3 = mildly ill, 4 = moderately ill, 5 = markedly ill, 6 = severely ill, 7 = among the most extremely ill. The CGI-S was assessed at Baseline, Week 1, Week 2 and Week 4. Data is presented representing the number of subjects who rated each CGI-S score at Baseline. (NCT00487942)
Timeframe: Baseline
| Intervention | Participants (Number) | ||||||
|---|---|---|---|---|---|---|---|
| Normal | Borderline ill | Mildly ill | Moderately ill | Markedly ill | Severely ill | Among the most extremely ill | |
| Armodafinil 100 mg/Day | 0 | 0 | 11 | 3 | 0 | 0 | 0 |
| Armodafinil 200 mg/Day | 0 | 1 | 8 | 3 | 0 | 0 | 0 |
| Armodafinil 50 mg/Day | 0 | 0 | 10 | 4 | 0 | 0 | 0 |
| Placebo | 0 | 0 | 11 | 2 | 0 | 0 | 0 |
The CGI-S is a standardized, clinician-rated assessment to rate the severity of illness of the patient. The clinician assessed the severity of illness using the following categories: 1 = normal, 2 = borderline ill, 3 = mildly ill, 4 = moderately ill, 5 = markedly ill, 6 = severely ill, 7 = among the most extremely ill. The CGI-S was assessed at Baseline, Week 1, Week 2 and Week 4. Data is presented representing the number of subjects who rated each CGI-S score at week 1. (NCT00487942)
Timeframe: Baseline and 1 week
| Intervention | Participants (Number) | ||||||
|---|---|---|---|---|---|---|---|
| Normal | Borderline ill | Mildly ill | Moderately ill | Markedly ill | Severely ill | Among the most extremely ill | |
| Armodafinil 100 mg/Day | 0 | 0 | 11 | 2 | 0 | 0 | 0 |
| Armodafinil 200 mg/Day | 0 | 1 | 8 | 2 | 0 | 0 | 0 |
| Armodafinil 50 mg/Day | 0 | 0 | 10 | 3 | 1 | 0 | 0 |
| Placebo | 0 | 0 | 11 | 1 | 1 | 0 | 0 |
The CGI-S is a standardized, clinician-rated assessment to rate the severity of illness of the patient. The clinician assessed the severity of illness using the following categories: 1 = normal, 2 = borderline ill, 3 = mildly ill, 4 = moderately ill, 5 = markedly ill, 6 = severely ill, 7 = among the most extremely ill. The CGI-S was assessed at Baseline, Week 1, Week 2 and Week 4. Data is presented representing the number of subjects who rated each CGI-S score at week 2. (NCT00487942)
Timeframe: Baseline and 2 weeks
| Intervention | Participants (Number) | ||||||
|---|---|---|---|---|---|---|---|
| Normal | Borderline ill | Mildly ill | Moderately ill | Markedly ill | Severely ill | Among the most extremely ill | |
| Armodafinil 100 mg/Day | 0 | 1 | 8 | 3 | 0 | 0 | 0 |
| Armodafinil 200 mg/Day | 0 | 1 | 10 | 1 | 0 | 0 | 0 |
| Armodafinil 50 mg/Day | 0 | 0 | 9 | 3 | 0 | 0 | 0 |
| Placebo | 0 | 0 | 11 | 1 | 0 | 0 | 0 |
The CGI-S is a standardized, clinician-rated assessment to rate the severity of illness of the patient. The clinician assessed the severity of illness using the following categories: 1 = normal, 2 = borderline ill, 3 = mildly ill, 4 = moderately ill, 5 = markedly ill, 6 = severely ill, 7 = among the most extremely ill. The CGI-S was assessed at Baseline, Week 1, Week 2 and Week 4. Data is presented representing the number of subjects who rated each CGI-S score at week 4. (NCT00487942)
Timeframe: Baseline and 4 weeks
| Intervention | Participants (Number) | ||||||
|---|---|---|---|---|---|---|---|
| Normal | Borderline ill | Mildly ill | Moderately ill | Markedly ill | Severely ill | Among the most extremely ill | |
| Armodafinil 100 mg/Day | 0 | 1 | 8 | 3 | 0 | 0 | 0 |
| Armodafinil 200 mg/Day | 0 | 1 | 10 | 1 | 0 | 0 | 0 |
| Armodafinil 50 mg/Day | 0 | 0 | 10 | 2 | 0 | 0 | 0 |
| Placebo | 0 | 0 | 11 | 1 | 0 | 0 | 0 |
The CGI-S is a standardized, clinician-rated assessment to rate the severity of illness of the patient. The clinician assessed the severity of illness using the following categories: 1 = normal, 2 = borderline ill, 3 = mildly ill, 4 = moderately ill, 5 = markedly ill, 6 = severely ill, 7 = among the most extremely ill. The CGI-S was assessed at Baseline, Week 1, Week 2 and Week 4. Data is presented representing the number of subjects who rated each CGI-S score at Endpoint which is Week 4 or the last observation following Baseline. (NCT00487942)
Timeframe: Baseline and 4 weeks (or last observation after Baseline)
| Intervention | Participants (Number) | ||||||
|---|---|---|---|---|---|---|---|
| Normal | Borderline ill | Mildly ill | Moderately ill | Markedly ill | Severely ill | Among the most extremely ill | |
| Armodafinil 100 mg/Day | 0 | 1 | 8 | 5 | 0 | 0 | 0 |
| Armodafinil 200 mg/Day | 0 | 1 | 10 | 1 | 0 | 0 | 0 |
| Armodafinil 50 mg/Day | 0 | 0 | 11 | 3 | 0 | 0 | 0 |
| Placebo | 0 | 0 | 11 | 2 | 0 | 0 | 0 |
The PGIC is a patient-rated scale of the change in disease severity. The PGIC uses the following 7 categories and scoring assignments: very much improved, much improved, minimally improved, no change, minimally worse, much worse, very much worse. The number of subjects who rated each category at Week 1 is presented here. (NCT00487942)
Timeframe: Week 1
| Intervention | Participants (Number) | ||||||
|---|---|---|---|---|---|---|---|
| Very much improved | Much improved | Minimally improved | No change | Minimally worse | Much worse | Very much worse | |
| Armodafinil 100 mg/Day | 2 | 1 | 0 | 10 | 0 | 0 | 0 |
| Armodafinil 200 mg/Day | 2 | 1 | 6 | 2 | 0 | 0 | 0 |
| Armodafinil 50 mg/Day | 1 | 1 | 2 | 9 | 0 | 1 | 0 |
| Placebo | 1 | 3 | 4 | 4 | 1 | 0 | 0 |
The PGIC is a patient-rated scale of the change in disease severity. The PGIC uses the following 7 categories and scoring assignments: very much improved, much improved, minimally improved, no change, minimally worse, much worse, very much worse. The number of subjects who rated each category at Week 2 is presented here. (NCT00487942)
Timeframe: Week 2
| Intervention | Participants (Number) | ||||||
|---|---|---|---|---|---|---|---|
| Very much improved | Much improved | Minimally improved | No change | Minimally worse | Much worse | Very much worse | |
| Armodafinil 100 mg/Day | 2 | 1 | 3 | 6 | 0 | 0 | 0 |
| Armodafinil 200 mg/Day | 2 | 3 | 5 | 2 | 0 | 0 | 0 |
| Armodafinil 50 mg/Day | 1 | 3 | 2 | 5 | 1 | 0 | 0 |
| Placebo | 3 | 4 | 2 | 3 | 0 | 0 | 0 |
The PGIC is a patient-rated scale of the change in disease severity. The PGIC uses the following 7 categories and scoring assignments: very much improved, much improved, minimally improved, no change, minimally worse, much worse, very much worse. The number of subjects who rated each category at Week 4 is presented here. (NCT00487942)
Timeframe: Week 4
| Intervention | Participants (Number) | ||||||
|---|---|---|---|---|---|---|---|
| Very much improved | Much improved | Minimally improved | No change | Minimally worse | Much worse | Very much worse | |
| Armodafinil 100 mg/Day | 2 | 2 | 4 | 4 | 0 | 0 | 0 |
| Armodafinil 200 mg/Day | 4 | 1 | 6 | 0 | 1 | 0 | 0 |
| Armodafinil 50 mg/Day | 1 | 3 | 7 | 0 | 0 | 1 | 0 |
| Placebo | 3 | 2 | 5 | 1 | 1 | 0 | 0 |
The PGIC is a patient-rated scale of the change in disease severity. The PGIC uses the following 7 categories and scoring assignments: very much improved, much improved, minimally improved, no change, minimally worse, much worse, very much worse. The number of subjects who rated each category at Week 4 or at the last observation following Baseline is presented. (NCT00487942)
Timeframe: Week 4 or last observation following Baseline
| Intervention | Participants (Number) | ||||||
|---|---|---|---|---|---|---|---|
| Very much improved | Much improved | Minimally improved | No change | Minimally worse | Much worse | Very much worse | |
| Armodafinil 100 mg/Day | 2 | 2 | 4 | 5 | 1 | 0 | 0 |
| Armodafinil 200 mg/Day | 4 | 1 | 6 | 0 | 1 | 0 | 0 |
| Armodafinil 50 mg/Day | 1 | 3 | 9 | 0 | 0 | 1 | 0 |
| Placebo | 3 | 2 | 5 | 2 | 1 | 0 | 0 |
Performance on tasks included in the Brief Assessment of Cognition in Schizophrenia (BACS) battery, task performed and results recorded on IPAD. The mean change from baseline in total cognitive score on the BACS was calculated as a weighted average of T-scores (normalized for age) from BACS subtests including Verbal Memory, Digit Sequencing, Token Motor, Symbol Coding, Semantic Fluency, Letter Fluency, and Tower of London. The minimum and maximum values possible for this composite T-score of the change from baseline were -131 and 131, respectively. Higher values (positive changes from baseline) indicate better performance. (NCT03288779)
Timeframe: 30 minutes
| Intervention | Composite T- Score (Mean) |
|---|---|
| Theta Burst Stimulation Arm | 37.33 |
(NCT00641745)
Timeframe: 12 months
| Intervention | participants (Number) |
|---|---|
| Lurasidone | 395 |
| Risperidone | 189 |
Barnes Akathisia Scale is a clinician rated scale which considers information based on observation of the participant as well as participant report. The scale includes 3 items rated between 0- none to 3 severe and 1 summary item rated between 0 none to 5 severe. All items are summed to obtain the total score. The minimal total score is 0 and the maximal score is 14 with higher scores reflecting more severe akathisia. A score of 4 or more is clinically significant. (NCT00053703)
Timeframe: 8 weeks
| Intervention | units on a scale (Mean) |
|---|---|
| Olanzapine | 0.19 |
| Risperidone | 0.41 |
| Molindone | 1.23 |
Change from baseline in Body Mass Index Change, kg/m2, at week 8, last observation was carried forward for individuals who withdrew from treatment early. (NCT00053703)
Timeframe: 8 weeks
| Intervention | kg/m2 (Mean) |
|---|---|
| Olanzapine | 1.27 |
| Risperidone | 2.20 |
| Molindone | 0.15 |
The PANSS (described above) includes 7 items that reflect negative psychotic symptoms such as amotivation and social withdrawal. As are all items within the PANSS, items are categorically rated by the clinician between 0 - no symptoms to 7 extreme symptoms. The minimal score is 0 reflecting no positive symptoms to 49 reflecting that all items were extreme. Higher scores reflect more severe symptoms. Scores above 18 are usually clinically significant. (NCT00053703)
Timeframe: 8 weeks
| Intervention | units on a scale (Mean) |
|---|---|
| Olanzapine | -5.3 |
| Risperidone | -5.1 |
| Molindone | -5.8 |
The PANSS (described above) includes 7 items that reflect positive psychotic symptoms such as hallucinations and delusions. As are all items within the PANSS, items are categorically rated by the clinician between 0 - no symptoms to 7 extreme symptoms. The minimal score is 0 reflecting no positive symptoms to 49 reflecting that all items were extreme. Higher scores reflect more severe symptoms. Scores above 18 are usually clinically significant. (NCT00053703)
Timeframe: 8 weeks
| Intervention | units on a scale (Mean) |
|---|---|
| Olanzapine | -8.9 |
| Risperidone | -8.4 |
| Molindone | -8.8 |
Assessed with the Positive and Negative Syndrome Scale in which a clinician rates various psychotic symptoms on the basis of observation of the participant, interview with the participant, and review of all other available information including informant reports. The scale consists of 30 items which are rated categorically between 1 - no symptoms to 7 - extreme symptoms. The minimal score is 0 and the maximal score is 210, with higher scores reflecting more symptoms. Typically scores > that 60 are considered clinically significant. (NCT00053703)
Timeframe: 8 weeks
| Intervention | units on a scale (Mean) |
|---|---|
| Olanzapine | -26.6 |
| Risperidone | -23.7 |
| Molindone | -27.0 |
change in weight from baseline to week 8 in kg (NCT00053703)
Timeframe: 8 weeks
| Intervention | Kg (Mean) |
|---|---|
| Olanzapine | 6.12 |
| Risperidone | 3.64 |
| Molindone | 0.34 |
"Facial Affect Perception Test that assesses the ability to accurately recognize facially expressed emotions as published by Smith et al 2014; Derntl et al., 2009. This scale ranges from 0-100 percent with a total of 30 trials. We examined the percent correct as the total number of correct responses divided by the total number of completed trials. There were no subscales. 100% accurate is the best outcome and 0% accurate is the worst outcome.~Cognitive Empathy Test that assesses the ability to accurately determine the emotional expression of another person as depicted in a static image of a social interaction as published by Smith et al 2014; Derntl et al., 2009. This scale ranges from 0-100 percent with a total of 60 trials. We examined the percent correct as the total number of correct responses divided by the total number of completed trials. There were no subscales. 100% accurate is the best outcome and 0% accurate is the worst outcome." (NCT01929889)
Timeframe: baseline and twelve weeks
| Intervention | units on a scale (Mean) | |
|---|---|---|
| Facial Affect Perception Test | Cognitive Empathy Test | |
| Iloperidone | 0 | -3.333 |
The T-score indicates the performance on a neurocognitive battery of tests. Higher score reflects better performance. (NCT02634684)
Timeframe: two visits, 1 week apart, each visit lasting approximately 6 hours
| Intervention | standardized T-score (Mean) | |
|---|---|---|
| placebo | amphetamine | |
| Healthy Subjects: 10 mg Amphetamine 1st, Then Placebo | 57.870 | 56.000 |
| Healthy Subjects: Placebo 1st, Then 10 mg Amphetamine | 54.476 | 55.476 |
| Subjects With Schizophrenia: 10 mg Amphetamine 1st, Then Placebo | 39.895 | 38.105 |
| Subjects With Schizophrenia: Placebo 1st, Then 10 mg Amphetamine | 31.895 | 33.842 |
"PPI was assessed with 42 trials of 6 types: 118 dB 40 ms pulse alone (P) & the same P preceded 10, 20, 30, 60, or 120 ms by a prepulse (pp) 16 dB over background. Startle magnitude (SM), habituation, latency & latency facilitation were measured to interpret changes in PPI.~%PPI = 100 x [(SM on P trials) - (SM on pp+P trials)] / SM on P trials. Example:~SM on P trials = 80 units SM on pp+P trials = 30 units %PPI = 100 x (80-30)/80 = 100 x 50/80 = 62.5%~Greater %PPI mean the reflex has been inhibited to a greater extent in the presence of a pp.~%PPI can't exceed 100: when SM on pp+P trials = 0, then %PPI = 100 x (SM on P trials - 0)/SM on P trials = 100 x 1 = 100%.~However, %PPI can theoretically be infinitely negative since SM on pp+P trials could be infinitely large (prepulse facilitiation (PPF)), i.e. SM is potentiated in the presence of a pp. PPF is normal at very short & very long pp intervals, but not within a species-specific physiological range of intervals." (NCT02634684)
Timeframe: two visits, 1 week apart, each visit lasting approximately 6 hours
| Intervention | % inhibition of startle (Mean) | |
|---|---|---|
| Placebo | Amphetamine | |
| Healthy Subjects: 10 mg Amphetamine 1st, Then Placebo | 50.626 | 53.029 |
| Healthy Subjects: Placebo 1st, Then 10 mg Amphetamine | 50.626 | 45.822 |
| Subjects With Schizophrenia: 10 mg Amphetamine 1st, Then Placebo | 41.162 | 39.545 |
| Subjects With Schizophrenia: Placebo 1st, Then 10 mg Amphetamine | 22.629 | 32.656 |
"Auditory discrimination learning: Subjects identify direction (up vs. down) of 2 consecutive sound sweeps. Parameters (e.g. inter-sweep interval, sweep duration) are established for subjects to maintain 80% correct responses. On screen and test days, subjects complete 1h of TCT. Analytic software yields the key measures: auditory processing speed (APS) and APS learning. APS is the shortest inter-stimulus interval at which a subject performs to criteria and APS learning is the difference (ms) between the first APS and the best APS of the subsequent trials. A smaller APS reflects better discrimination (i.e., subject correctly identified frequency sweep direction despite a smaller ms gap between stimuli) and a larger ms value for APS learning reflects more learning, i.e., faster APS with repeated trials. Limits for APS are capped at 0-to-1000 ms; values for APS learning are capped at (-) 1000-to-APS." (NCT02634684)
Timeframe: two visits, 1 week apart, each visit lasting approximately 6 hours
| Intervention | msec (Mean) | |
|---|---|---|
| placebo | amphetamine | |
| Healthy Subjects: 10 mg Amphetamine 1st, Then Placebo | -2.113 | 29.190 |
| Healthy Subjects: Placebo 1st, Then 10 mg Amphetamine | 5.911 | 35.905 |
| Subjects With Schizophrenia: 10 mg Amphetamine 1st, Then Placebo | -50.158 | 101.000 |
| Subjects With Schizophrenia: Placebo 1st, Then 10 mg Amphetamine | -15.118 | 52.647 |
"Scans will be analyzed for task-related prefrontal activation~Difference Score: Percent Signal Change in Regions of Interest (ketamine - saline)" (NCT01600885)
Timeframe: Within 4 hours of dose administration, after up to 1.25 hours of ketamine infusion
| Intervention | percent change in saline signal (Mean) |
|---|---|
| Guanfacine | -0.17 |
| Placebo | -0.094 |
Difference Score: Percent Signal Change in Regions of Interest (ketamine - saline) (NCT01600885)
Timeframe: Within 4 hours of dose administration, after up to 1.25 hours of ketamine infusion
| Intervention | percent change in saline signal (Mean) |
|---|---|
| Guanfacine | -0.1 |
| Placebo | 0.052 |
Difference Score: Percent Signal Change in Regions of Interest (ketamine - saline) (NCT01600885)
Timeframe: Within 4 hours of dose administration, after up to 1.25 hours of ketamine infusion
| Intervention | percent change in saline signal (Mean) |
|---|---|
| Guanfacine | -0.134 |
| Placebo | -0.086 |
16 reviews available for risperidone and Cognition Disorders
| Article | Year |
|---|---|
[Optimal Antipsychotic Dose and Dosing Interval in the Treatment of Schizophrenia].
Topics: Antipsychotic Agents; Cognition Disorders; Drug Administration Schedule; Humans; Risperidone; Schizo | 2015 |
[Working memory in schizophrenia: a review].
Topics: Antipsychotic Agents; Cognition Disorders; Humans; Memory Disorders; Memory, Short-Term; Neuropsycho | 2008 |
Cognitive and psychomotor effects of risperidone in schizophrenia and schizoaffective disorder.
Topics: Antipsychotic Agents; Attention; Cognition; Cognition Disorders; Double-Blind Method; Humans; Psycho | 2008 |
Risperidone for the treatment of neuropsychiatric features in dementia.
Topics: Accidental Falls; Aged; Aged, 80 and over; Antipsychotic Agents; Cerebrovascular Disorders; Cognitio | 2006 |
[The use of atypical antipsychotics in the long-term care of schizophrenia].
Topics: Amisulpride; Antipsychotic Agents; Aripiprazole; Basal Ganglia Diseases; Benzodiazepines; Clozapine; | 2006 |
The effects of clozapine on neurocognition: an overview.
Topics: Clozapine; Cognition; Cognition Disorders; Dopamine; Humans; Isoxazoles; Neuropsychological Tests; P | 1994 |
The role of cognition in the risk--benefit and safety analysis of antipsychotic medication.
Topics: Antipsychotic Agents; Cognition Disorders; Humans; Neuropsychological Tests; Prefrontal Cortex; Rece | 1996 |
Measuring outcome in schizophrenia: differences among the atypical antipsychotics. Collaborative Working Group on Clinical Trial Evaluations.
Topics: Antipsychotic Agents; Benzodiazepines; Clozapine; Cognition Disorders; Cost-Benefit Analysis; Dibenz | 1998 |
Evaluating the effects of antipsychotics on cognition in schizophrenia. Collaborative Working Group on Clinical Trial Evaluations.
Topics: Antipsychotic Agents; Clinical Trials as Topic; Clozapine; Cognition Disorders; Dibenzothiazepines; | 1998 |
Will the novel antipsychotics significantly ameliorate neuropsychological deficits and improve adaptive functioning in schizophrenia?
Topics: Antipsychotic Agents; Basal Ganglia Diseases; Clozapine; Cognition Disorders; Humans; Reaction Time; | 1999 |
Cognitive improvement in schizophrenia with novel antipsychotic medications.
Topics: Antipsychotic Agents; Benzodiazepines; Clozapine; Cognition Disorders; Dibenzothiazepines; Humans; O | 1999 |
Cognitive deficit in schizophrenia and its neurochemical basis.
Topics: Antipsychotic Agents; Benzodiazepines; Clozapine; Cognition Disorders; Glutamic Acid; Haloperidol; H | 1999 |
The effects of clozapine, risperidone, and olanzapine on cognitive function in schizophrenia.
Topics: Antipsychotic Agents; Attention; Benzodiazepines; Clinical Trials as Topic; Clozapine; Cognition Dis | 1999 |
Olanzapine: an updated review of its use in the management of schizophrenia.
Topics: Adolescent; Aged; Animals; Antipsychotic Agents; Benzodiazepines; Child; Child, Preschool; Cognition | 2001 |
Risperidone for the treatment of behavioral and psychological symptoms of dementia.
Topics: Aged; Aggression; Antipsychotic Agents; Basal Ganglia Diseases; Clinical Trials as Topic; Cognition | 2001 |
[Clinical and pharmacological studies of the second generation antipsychotics].
Topics: Antipsychotic Agents; Benzodiazepines; Clozapine; Cognition Disorders; Cytoskeletal Proteins; Dibenz | 2001 |
81 trials available for risperidone and Cognition Disorders
| Article | Year |
|---|---|
Different neurocognitive profiles of risperidone and aripiprazole in the FIRST episode of psychosis: A 3-year follow-up comparison.
Topics: Adolescent; Adult; Antipsychotic Agents; Aripiprazole; Cognition; Cognition Disorders; Cohort Studie | 2021 |
Effects of risperidone and olanzapine dose reduction on cognitive function in stable patients with schizophrenia: an open-label, randomized, controlled, pilot study.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Cognition Disorders; Drug Administration Schedule; Fem | 2013 |
The influence of switching from risperidone to paliperidone on the extrapyramidal symptoms and cognitive function in elderly patients with schizophrenia: a preliminary open-label trial.
Topics: Aged; Akathisia, Drug-Induced; Antipsychotic Agents; Cognition Disorders; Drug Substitution; Dyskine | 2014 |
Minocycline supplementation for treatment of negative symptoms in early-phase schizophrenia: a double blind, randomized, controlled trial.
Topics: Adult; Analysis of Variance; Antipsychotic Agents; Cognition Disorders; Double-Blind Method; Female; | 2014 |
Effects of risperidone and aripiprazole on neurocognitive rehabilitation for schizophrenia.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Cognition Disorders; Drug Synergism; Female; Humans; Male | 2014 |
Relationship of Cognition to Clinical Response in First-Episode Schizophrenia Spectrum Disorders.
Topics: Adolescent; Adult; Antipsychotic Agents; Aripiprazole; Cognition Disorders; Female; Humans; Male; Ou | 2015 |
Clinical symptom responses to atypical antipsychotic medications in Alzheimer's disease: phase 1 outcomes from the CATIE-AD effectiveness trial.
Topics: Activities of Daily Living; Aged; Aggression; Alzheimer Disease; Antipsychotic Agents; Benzodiazepin | 2008 |
Cognitive effects of risperidone in children with autism and irritable behavior.
Topics: Adolescent; Autistic Disorder; Child; Child Behavior Disorders; Child, Preschool; Cognition; Cogniti | 2008 |
Added ondansetron for stable schizophrenia: a double blind, placebo controlled trial.
Topics: Adult; Antipsychotic Agents; Case-Control Studies; Chronic Disease; Cognition Disorders; Double-Blin | 2009 |
Trajectories and antecedents of treatment response over time in early-episode psychosis.
Topics: Adult; Age of Onset; Antipsychotic Agents; Cognition Disorders; Double-Blind Method; Early Diagnosis | 2010 |
[Effects of the anticholinesterase drug neuromidin in patients with schizophrenia with marked neurocognitive deficits].
Topics: Aminoquinolines; Antipsychotic Agents; Brain; Cholinesterase Inhibitors; Cognition Disorders; Drug T | 2008 |
Lack of an inverse relationship between duration of untreated psychosis and cognitive function in first episode schizophrenia.
Topics: Adolescent; Antipsychotic Agents; Benzodiazepines; Cognition Disorders; Double-Blind Method; Early D | 2009 |
Lack of association between clinical and cognitive change in first-episode psychosis: the first 6 weeks of treatment.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Cognition Disorders; Female; Haloperidol; Humans; Male | 2008 |
Neurocognitive effectiveness of haloperidol, risperidone, and olanzapine in first-episode psychosis: a randomized, controlled 1-year follow-up comparison.
Topics: Adult; Amisulpride; Antipsychotic Agents; Benzodiazepines; Brain; Clozapine; Cognition Disorders; Fe | 2009 |
Effect of risperidone on emotion recognition deficits in antipsychotic-naïve schizophrenia: a short-term follow-up study.
Topics: Adolescent; Adult; Antipsychotic Agents; Cognition Disorders; Cognitive Behavioral Therapy; Emotions | 2009 |
The effects of risperidone on the cognitive performance of individuals with schizotypal personality disorder.
Topics: Adolescent; Adult; Antipsychotic Agents; Cognition; Cognition Disorders; Female; Humans; Male; Middl | 2009 |
Relationships among neurocognition, symptoms and functioning in patients with schizophrenia: a path-analytic approach for associations at baseline and following 24 weeks of antipsychotic drug therapy.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Cognition Disorders; Female; Follow-Up Studies; Halope | 2009 |
Effects of switching to long-acting injectable risperidone from oral atypical antipsychotics on cognitive function in patients with schizophrenia.
Topics: Adolescent; Adult; Analysis of Variance; Antipsychotic Agents; Cognition; Cognition Disorders; Drug | 2009 |
Dopaminergic modulation of rapid reality adaptation in thinking.
Topics: Adaptation, Psychological; Adult; Brain; Cognition Disorders; Dopamine; Dopamine Agents; Dopamine An | 2010 |
Armodafinil as adjunctive therapy in adults with cognitive deficits associated with schizophrenia: a 4-week, double-blind, placebo-controlled study.
Topics: Adult; Antipsychotic Agents; Benzhydryl Compounds; Benzodiazepines; Central Nervous System Stimulant | 2010 |
Galantamine augmentation of long-acting injectable risperidone for cognitive impairments in chronic schizophrenia.
Topics: Adult; Antipsychotic Agents; Chronic Disease; Cognition Disorders; Delayed-Action Preparations; Dose | 2011 |
Characteristics of the MATRICS Consensus Cognitive Battery in a 29-site antipsychotic schizophrenia clinical trial.
Topics: Adult; Antipsychotic Agents; Cognition Disorders; Female; Humans; Isoindoles; Lurasidone Hydrochlori | 2011 |
Characteristics of the MATRICS Consensus Cognitive Battery in a 29-site antipsychotic schizophrenia clinical trial.
Topics: Adult; Antipsychotic Agents; Cognition Disorders; Female; Humans; Isoindoles; Lurasidone Hydrochlori | 2011 |
Characteristics of the MATRICS Consensus Cognitive Battery in a 29-site antipsychotic schizophrenia clinical trial.
Topics: Adult; Antipsychotic Agents; Cognition Disorders; Female; Humans; Isoindoles; Lurasidone Hydrochlori | 2011 |
Characteristics of the MATRICS Consensus Cognitive Battery in a 29-site antipsychotic schizophrenia clinical trial.
Topics: Adult; Antipsychotic Agents; Cognition Disorders; Female; Humans; Isoindoles; Lurasidone Hydrochlori | 2011 |
Mirtazapine augmentation enhances cognitive and reduces negative symptoms in schizophrenia patients treated with risperidone: a randomized controlled trial.
Topics: Adult; Antidepressive Agents, Tricyclic; Antipsychotic Agents; Cognition Disorders; Double-Blind Met | 2011 |
Cognitive effects of atypical antipsychotic medications in patients with Alzheimer's disease: outcomes from CATIE-AD.
Topics: Activities of Daily Living; Aged; Aged, 80 and over; Alzheimer Disease; Antipsychotic Agents; Benzod | 2011 |
Effect of adjunctive treatment with aripiprazole to atypical antipsychotics on cognitive function in schizophrenia patients.
Topics: Adult; Antidepressive Agents, Second-Generation; Antipsychotic Agents; Aripiprazole; Benzodiazepines | 2012 |
A validation of cognitive biomarkers for the early identification of cognitive enhancing agents in schizotypy: a three-center double-blind placebo-controlled study.
Topics: Adult; Amisulpride; Analysis of Variance; Biomarkers; Cognition Disorders; Double-Blind Method; Fema | 2012 |
Dopamine D2 receptor occupancy and cognition in schizophrenia: analysis of the CATIE data.
Topics: Adolescent; Adult; Antipsychotic Agents; Benzodiazepines; Cognition Disorders; Dopamine D2 Receptor | 2013 |
Neurocognitive outcomes in the Treatment of Early-Onset Schizophrenia Spectrum Disorders study.
Topics: Adolescent; Antipsychotic Agents; Benzodiazepines; Child; Cognition Disorders; Double-Blind Method; | 2012 |
Double-blind placebo-controlled randomized efficacy and safety trial of add-on treatment of dimebon plus risperidone in schizophrenic patients during transition from acute psychotic episode to remission.
Topics: Acute Disease; Adult; Antipsychotic Agents; Cognition Disorders; Drug Therapy, Combination; Humans; | 2012 |
Paliperidone ER versus risperidone for neurocognitive function in patients with schizophrenia: a randomized, open-label, controlled trial.
Topics: Adolescent; Adult; Antipsychotic Agents; Cognition Disorders; Delayed-Action Preparations; Depressio | 2012 |
Cognition and communication dysfunctions in early-onset schizophrenia: effect of risperidone.
Topics: Adolescent; Adolescent Behavior; Antipsychotic Agents; Cognition Disorders; Communication Disorders; | 2012 |
Effect of antipsychotic drugs on cortical thickness. A randomized controlled one-year follow-up study of haloperidol, risperidone and olanzapine.
Topics: Adolescent; Adult; Aged; Analysis of Variance; Antipsychotic Agents; Benzodiazepines; Cerebral Corte | 2012 |
Construct validity of 2 measures to assess reasons for antipsychotic discontinuation and continuation from patients' and clinicians' perspectives in a clinical trial.
Topics: Adult; Antipsychotic Agents; Cognition Disorders; Double-Blind Method; Female; Humans; Interview, Ps | 2012 |
Duration of untreated negative and positive symptoms of psychosis and cognitive impairment in first episode psychosis.
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Benzodiazepines; Cognition Disorders; Female; Humans; | 2012 |
The influence of switching from haloperidol decanoate depot to risperidone long-acting injection on the clinical symptoms and cognitive function in schizophrenia.
Topics: Adult; Aged; Antipsychotic Agents; Cognition Disorders; Delayed-Action Preparations; Diagnosis, Comp | 2012 |
Bl-1020, a new γ-aminobutyric acid-enhanced antipsychotic: results of 6-week, randomized, double-blind, controlled, efficacy and safety study.
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Cognition Disorders; Dopamine Antagonists; Double-Bli | 2012 |
Identification of clinically meaningful relationships among cognition, functionality, and symptoms in subjects with schizophrenia or schizoaffective disorder.
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Cognition Disorders; Double-Blind Method; Female; Hum | 2013 |
Clozapine and visuospatial processing in treatment-resistant schizophrenia.
Topics: Adolescent; Adult; Antipsychotic Agents; Benzodiazepines; Clozapine; Cognition; Cognition Disorders; | 2013 |
Cross-national cognitive assessment in schizophrenia clinical trials: a feasibility study.
Topics: Adult; Antipsychotic Agents; Australia; Austria; Canada; Clinical Trials as Topic; Cognition Disorde | 2003 |
Differential effects of olanzapine and risperidone on cognition in schizophrenia? A saccadic eye movement study.
Topics: Adolescent; Adult; Antipsychotic Agents; Benzodiazepines; Cognition Disorders; Female; Humans; Male; | 2002 |
Changes in cognitive functioning with risperidone and olanzapine treatment: a large-scale, double-blind, randomized study.
Topics: Adolescent; Adult; Arousal; Benzodiazepines; Cognition Disorders; Diagnostic and Statistical Manual | 2003 |
Risperidone and olanzapine in adults with intellectual disability: a clinical naturalistic study.
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Benzodiazepines; Cognition Disorders; Comorbidity; Di | 2003 |
Comparative effects of risperidone and olanzapine on cognition in elderly patients with schizophrenia or schizoaffective disorder.
Topics: Aged; Antipsychotic Agents; Benzodiazepines; Cognition Disorders; Double-Blind Method; Female; Human | 2003 |
Risperidone response and 5-HT6 receptor gene variance: genetic association analysis with adjustment for nongenetic confounders.
Topics: Acute Disease; Adolescent; Adult; Antipsychotic Agents; Cognition Disorders; Depression; Female; Gen | 2004 |
Do clozapine and risperidone affect social competence and problem solving?
Topics: Adult; Clozapine; Cognition Disorders; Double-Blind Method; Female; Humans; Male; Neuropsychological | 2004 |
Correlates of cognitive deficits in first episode schizophrenia.
Topics: Adolescent; Adult; Antipsychotic Agents; Cognition Disorders; Diagnostic and Statistical Manual of M | 2004 |
Long-term, open-label study of risperidone in children with severe disruptive behaviors and below-average IQ.
Topics: Antipsychotic Agents; Attention Deficit and Disruptive Behavior Disorders; Child; Child, Preschool; | 2004 |
Risperidone in the treatment of patients with delirium.
Topics: Aged; Antipsychotic Agents; Cognition Disorders; Delirium; Female; Health Status; Humans; Male; Midd | 2004 |
Antipsychotic and anticholinergic effects on two types of spatial memory in schizophrenia.
Topics: Adult; Antipsychotic Agents; Benztropine; Cholinergic Antagonists; Cognition Disorders; Female; Huma | 2004 |
A comparison of two novel antipsychotics in first episode non-affective psychosis: one-year outcome on symptoms, motor side effects and cognition.
Topics: Adolescent; Adult; Antipsychotic Agents; Basal Ganglia Diseases; Benzodiazepines; Cognition Disorder | 2004 |
Risperidone in children with disruptive behavior disorders and subaverage intelligence: a 1-year, open-label study of 504 patients.
Topics: Adolescent; Antipsychotic Agents; Attention Deficit and Disruptive Behavior Disorders; Child; Child, | 2005 |
Correlates of anticholinergic activity in patients with dementia and psychosis treated with risperidone or olanzapine.
Topics: Antipsychotic Agents; Basal Ganglia Diseases; Benzodiazepines; Cognition Disorders; Delusions; Demen | 2004 |
Risperidone and haloperidol augmentation of serotonin reuptake inhibitors in refractory obsessive-compulsive disorder: a crossover study.
Topics: Adult; Antipsychotic Agents; Cognition Disorders; Cross-Over Studies; Double-Blind Method; Drug Ther | 2005 |
Cerebral cortical gray expansion associated with two second-generation antipsychotics.
Topics: Adult; Antipsychotic Agents; Atrophy; Cerebral Cortex; Cognition Disorders; Female; Follow-Up Studie | 2005 |
The effect of neuroleptic treatments on executive function and symptomatology in schizophrenia: a 1-year follow up study.
Topics: Adult; Antipsychotic Agents; Brain; Cognition; Cognition Disorders; Double-Blind Method; Female; Fol | 2005 |
Treatment of cognitive impairment in early psychosis: a comparison of risperidone and haloperidol in a large long-term trial.
Topics: Adult; Age of Onset; Antipsychotic Agents; Cognition Disorders; Double-Blind Method; Drug Administra | 2005 |
Comparison of quetiapine and risperidone in the treatment of schizophrenia: A randomized, double-blind, flexible-dose, 8-week study.
Topics: Adult; Antipsychotic Agents; Basal Ganglia Diseases; Cognition Disorders; Dibenzothiazepines; Disord | 2006 |
Improvement in social competence with short-term atypical antipsychotic treatment: a randomized, double-blind comparison of quetiapine versus risperidone for social competence, social cognition, and neuropsychological functioning.
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Cognition Disorders; Dibenzothiazepines; Double-Blind | 2006 |
A double-blind study of combination of clozapine with risperidone in patients with schizophrenia: effects on cognition.
Topics: Adult; Antipsychotic Agents; Attention; Clozapine; Cognition; Cognition Disorders; Double-Blind Meth | 2006 |
A placebo-controlled add-on trial of the Ampakine, CX516, for cognitive deficits in schizophrenia.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Clozapine; Cognition Disorders; Dioxoles; Double-Blind | 2008 |
Effect of olanzapine or risperidone treatment on some cognitive functions in a one-year follow-up of schizophrenia outpatients with prominent negative symptoms.
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Benzodiazepines; Cognition Disorders; Female; Follow- | 2007 |
Neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE Trial.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Cognition Disorders; Cohort Studies; Dibenzothiazepine | 2007 |
Effects of olanzapine, quetiapine, and risperidone on neurocognitive function in early psychosis: a randomized, double-blind 52-week comparison.
Topics: Adult; Antipsychotic Agents; Attitude to Health; Benzodiazepines; Cognition Disorders; Dibenzothiaze | 2007 |
Cognitive functioning and acute sedative effects of risperidone and quetiapine in patients with stable bipolar I disorder: a randomized, double-blind, crossover study.
Topics: Adult; Antipsychotic Agents; Attention; Bipolar Disorder; Cognition; Cognition Disorders; Dibenzothi | 2007 |
Cognitive improvement after treatment with second-generation antipsychotic medications in first-episode schizophrenia: is it a practice effect?
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Cognition; Cognition Disorders; Control Groups; Female | 2007 |
The impact of insight on functioning in patients with schizophrenia or schizoaffective disorder receiving risperidone long-acting injectable.
Topics: Activities of Daily Living; Adult; Antipsychotic Agents; Awareness; Cognition Disorders; Delayed-Act | 2007 |
Predictors of treatment discontinuation and medication nonadherence in patients recovering from a first episode of schizophrenia, schizophreniform disorder, or schizoaffective disorder: a randomized, double-blind, flexible-dose, multicenter study.
Topics: Adult; Antipsychotic Agents; Attitude to Health; Benzodiazepines; Cognition Disorders; Culture; Dibe | 2008 |
Different side effect profiles of risperidone and clozapine in 20 outpatients with schizophrenia or schizoaffective disorder: a pilot study.
Topics: Akathisia, Drug-Induced; Ambulatory Care; Clozapine; Cognition Disorders; Cross-Over Studies; Humans | 1996 |
Risperidone, negative symptoms and cognitive deficit in schizophrenia: an open study.
Topics: Adult; Affective Symptoms; Antipsychotic Agents; Cognition Disorders; Female; Humans; Male; Middle A | 1997 |
Neurocognitive functioning in schizophrenia: a trial of risperidone versus haloperidol.
Topics: Antipsychotic Agents; Cognition Disorders; Double-Blind Method; Haloperidol; Humans; Neuropsychologi | 1997 |
A structured trial of risperidone for the treatment of agitation in dementia.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Analysis of Variance; Antipsychotic Agents; Basal Gangli | 1998 |
Clinical and neurocognitive effects of clozapine and risperidone in treatment-refractory schizophrenic patients: a prospective study.
Topics: Adult; Basal Ganglia Diseases; Clozapine; Cognition Disorders; Female; Humans; Male; Middle Aged; Ne | 1998 |
Treatment of nonpsychotic relatives of patients with schizophrenia: four case studies.
Topics: Adult; Antipsychotic Agents; Attention; Behavioral Symptoms; Cognition Disorders; Family Health; Fem | 1999 |
The course of depressive symptoms in predicting relapse in schizophrenia: a double-blind, randomized comparison of olanzapine and risperidone.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Cluster Analysis; Cognition Disorders; Depressive Diso | 1999 |
Neuropsychological change in early phase schizophrenia during 12 months of treatment with olanzapine, risperidone, or haloperidol. The Canadian Collaborative Group for research in schizophrenia.
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Benzodiazepines; Cognition Disorders; Double-Blind Me | 2000 |
Practice-related improvement in information processing with novel antipsychotic treatment.
Topics: Adult; Antipsychotic Agents; Cognition Disorders; Female; Hospitalization; Hospitals, Psychiatric; H | 2000 |
Guanfacine treatment of cognitive impairment in schizophrenia.
Topics: Adrenergic alpha-Agonists; Adult; Antipsychotic Agents; Cognition Disorders; Double-Blind Method; Fe | 2001 |
Guanfacine treatment of cognitive impairment in schizophrenia.
Topics: Adrenergic alpha-Agonists; Adult; Antipsychotic Agents; Cognition Disorders; Double-Blind Method; Fe | 2001 |
Guanfacine treatment of cognitive impairment in schizophrenia.
Topics: Adrenergic alpha-Agonists; Adult; Antipsychotic Agents; Cognition Disorders; Double-Blind Method; Fe | 2001 |
Guanfacine treatment of cognitive impairment in schizophrenia.
Topics: Adrenergic alpha-Agonists; Adult; Antipsychotic Agents; Cognition Disorders; Double-Blind Method; Fe | 2001 |
The effect of risperidone on cognitive functioning in a sample of Asian patients with schizophrenia in Singapore.
Topics: Adult; Antipsychotic Agents; Cognition; Cognition Disorders; Female; Humans; Male; Middle Aged; Risp | 2001 |
Effect of risperidone on behavioral and psychological symptoms and cognitive function in dementia.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Antipsychotic Agents; Basal Ganglia Diseases; Caregivers | 2001 |
Relationship between neuroleptic dosage and subjective cognitive dysfunction in schizophrenic patients treated with either conventional or atypical neuroleptic medication.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Clozapine; Cognition Disorders; Dose-Response Relation | 2002 |
A double blind placebo controlled trial of donepezil adjunctive treatment to risperidone for the cognitive impairment of schizophrenia.
Topics: Adult; Aged; Antipsychotic Agents; Cognition Disorders; Donepezil; Dose-Response Relationship, Drug; | 2002 |
68 other studies available for risperidone and Cognition Disorders
| Article | Year |
|---|---|
Cognitive enhancer ST101 improves schizophrenia-like behaviors in neonatal ventral hippocampus-lesioned rats in association with improved CaMKII/PKC pathway.
Topics: Animals; Animals, Newborn; Antipsychotic Agents; Calcium-Calmodulin-Dependent Protein Kinase Type 2; | 2019 |
BDNF serum levels and cognitive improvement in drug-naive first episode patients with schizophrenia: A prospective 12-week longitudinal study.
Topics: Adult; Antipsychotic Agents; Brain-Derived Neurotrophic Factor; Cognition; Cognition Disorders; Cogn | 2020 |
Risperidone ameliorates cognitive deficits, promotes hippocampal proliferation, and enhances Notch signaling in a murine model of schizophrenia.
Topics: Animals; Cognition Disorders; Disease Models, Animal; Hippocampus; Male; Mice; Mice, Inbred C57BL; R | 2017 |
Donepezil and the alpha-7 agonist PHA 568487, but not risperidone, ameliorate spatial memory deficits in a subchronic MK-801 mouse model of cognitive impairment in schizophrenia.
Topics: Acetylcholinesterase; alpha7 Nicotinic Acetylcholine Receptor; Animals; Antipsychotic Agents; Aza Co | 2014 |
Greater clinical and cognitive improvement with clozapine and risperidone associated with a thinner cortex at baseline in first-episode schizophrenia.
Topics: Adult; Antipsychotic Agents; Clozapine; Cognition Disorders; Disease Progression; Female; Follow-Up | 2014 |
Divergent long-term consequences of chronic treatment with haloperidol, risperidone, and bromocriptine on traumatic brain injury-induced cognitive deficits.
Topics: Animals; Antipsychotic Agents; Behavior, Animal; Brain Injuries; Bromocriptine; Cognition Disorders; | 2015 |
Nest building is impaired in the Ts65Dn mouse model of Down syndrome and rescued by blocking 5HT2a receptors.
Topics: Animals; Cognition Disorders; Disease Models, Animal; Down Syndrome; Gene Expression; Mice; Nesting | 2014 |
Cognitive differences in schizophrenia on long-term treatments with clozapine, risperidone and typical antipsychotics.
Topics: Adult; Aged; Antipsychotic Agents; Case-Control Studies; Clozapine; Cognition Disorders; Cross-Secti | 2015 |
Examining Huntington's disease patient and informant concordance on frontally mediated behaviors.
Topics: Adult; Aged; Antipsychotic Agents; Awareness; Cognition Disorders; Disease Progression; Female; Fron | 2015 |
Effects of cariprazine, a novel antipsychotic, on cognitive deficit and negative symptoms in a rodent model of schizophrenia symptomatology.
Topics: Animals; Antipsychotic Agents; Cognition; Cognition Disorders; Conditioning, Operant; Disease Models | 2016 |
[Cognitive effectiveness of risperidone and olanzapine in first-episode schizophrenia].
Topics: Antipsychotic Agents; Benzodiazepines; Cognition; Cognition Disorders; Humans; Olanzapine; Risperido | 2016 |
Risperidone ameliorated Aβ
Topics: Alzheimer Disease; Amyloid beta-Peptides; Amyloid Precursor Protein Secretases; Animals; Apoptosis; | 2017 |
Spatial working memory and problem solving in schizophrenia: the effect of symptom stabilization with atypical antipsychotic medication.
Topics: Adult; Antipsychotic Agents; Clozapine; Cognition Disorders; Control Groups; Female; Follow-Up Studi | 2008 |
The subjective experience of taking antipsychotic medication: a content analysis of Internet data.
Topics: Adult; Affect; Akathisia, Drug-Induced; Antipsychotic Agents; Anxiety Disorders; Attitude to Health; | 2009 |
Association studies of catechol-O-methyltransferase (COMT) gene with schizophrenia and response to antipsychotic treatment.
Topics: Adult; Antipsychotic Agents; Case-Control Studies; Catechol O-Methyltransferase; Cognition Disorders | 2009 |
[Oniric activity in the onset of psychosis: the dreams of a schizophrenic].
Topics: Aggression; Antipsychotic Agents; Cognition Disorders; Delusions; Dreams; Female; Humans; Neuropsych | 2010 |
Deletion of CB2 cannabinoid receptor induces schizophrenia-related behaviors in mice.
Topics: Acoustic Stimulation; Analysis of Variance; Animals; Antipsychotic Agents; Anxiety; Avoidance Learni | 2011 |
Preclinical assessment of an adjunctive treatment approach for cognitive impairment associated with schizophrenia using the alpha7 nicotinic acetylcholine receptor agonist WYE-103914/SEN34625.
Topics: alpha7 Nicotinic Acetylcholine Receptor; Animals; Antipsychotic Agents; Avoidance Learning; Cognitio | 2011 |
The voices go, but the song remains the same: how can we rescue cognition in early-onset schizophrenia?
Topics: Antipsychotic Agents; Benzodiazepines; Cognition Disorders; Female; Humans; Male; Molindone; Neurops | 2012 |
Could repetitive transcranial magnetic stimulation improve neurocognition in early-onset schizophrenia spectrum disorders?
Topics: Antipsychotic Agents; Benzodiazepines; Cognition Disorders; Female; Humans; Male; Molindone; Neurops | 2012 |
Recovery in schizophrenia: focus on neurocognitive functioning.
Topics: Adult; Antipsychotic Agents; Arousal; Attention; Cognition Disorders; Executive Function; Female; Hu | 2012 |
Decreased CaMKII and PKC activities in specific brain regions are associated with cognitive impairment in neonatal ventral hippocampus-lesioned rats.
Topics: Animals; Animals, Newborn; Antipsychotic Agents; Calcium-Calmodulin-Dependent Protein Kinase Type 2; | 2013 |
Mismatch negativity and cognitive performance for the prediction of psychosis in subjects with at-risk mental state.
Topics: Adolescent; Adult; Antipsychotic Agents; Aripiprazole; Cognition Disorders; Electroencephalography; | 2013 |
Comparable dopamine 2 receptor occupancy.
Topics: Benzodiazepines; Cognition Disorders; Dopamine Antagonists; Haloperidol; Humans; Olanzapine; Pirenze | 2002 |
Insight in persons with schizophrenia: effects of switching from conventional neuroleptics to atypical antipsychotics.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Clozapine; Cognition; Cognition Disorders; Female; Hal | 2002 |
Does risperidone act better in schizophrenic patients who have a family or obstetric history?
Topics: Adolescent; Adult; Age of Onset; Antipsychotic Agents; Cognition Disorders; Female; Humans; Male; Me | 2002 |
Atypical antipsychotic drugs improve cognition in schizophrenia.
Topics: Antipsychotic Agents; Cognition Disorders; Double-Blind Method; Follow-Up Studies; Haloperidol; Huma | 2003 |
Future employability, a new approach to cost-effectiveness analysis of antipsychotic therapy.
Topics: Adult; Antipsychotic Agents; Cognition Disorders; Cost-Benefit Analysis; Drug Administration Schedul | 2003 |
[Neuroleptics and cognition].
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Clozapine; Cognition Disorders; Drug Therapy, Combinat | 2003 |
Role of dopamine D3 receptor (DRD3) and dopamine transporter (DAT) polymorphism in cognitive dysfunctions and therapeutic response to atypical antipsychotics in patients with schizophrenia.
Topics: Adult; Alleles; Analysis of Variance; Antipsychotic Agents; Benzodiazepines; Clozapine; Cognition Di | 2004 |
Effectiveness of antipsychotic treatments for schizophrenia: interim 6-month analysis from a prospective observational study (IC-SOHO) comparing olanzapine, quetiapine, risperidone, and haloperidol.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Cognition Disorders; Diagnostic and Statistical Manual | 2004 |
The management of psychogeriatric patient.
Topics: Activities of Daily Living; Aged; Aged, 80 and over; Aggression; Alzheimer Disease; Antipsychotic Ag | 2004 |
Child and adolescent electroconvulsive therapy: a case report.
Topics: Adolescent; Antipsychotic Agents; Child; Cognition Disorders; Combined Modality Therapy; Depressive | 2004 |
Risperidone for resistant anxiety in elderly persons.
Topics: Aged; Aged, 80 and over; Anti-Anxiety Agents; Antipsychotic Agents; Anxiety; Cognition Disorders; Dr | 2005 |
Adjuvant galantamine to risperidone improves negative and cognitive symptoms in a patient presenting with schizophrenialike psychosis after traumatic brain injury.
Topics: Adult; Antipsychotic Agents; Brain Hemorrhage, Traumatic; Cholinesterase Inhibitors; Cognition Disor | 2005 |
Neurocognitive function in unmedicated manic and medicated euthymic pediatric bipolar patients.
Topics: Adolescent; Anticonvulsants; Antipsychotic Agents; Attention Deficit Disorder with Hyperactivity; Bi | 2006 |
Antipsychotic treatment improves outcome in herpes simplex encephalitis: a case report.
Topics: Adult; Antipsychotic Agents; Cognition Disorders; Comorbidity; Delusions; Encephalitis, Herpes Simpl | 2006 |
A case of schizophrenia with complete agenesis of the corpus callosum.
Topics: Adult; Agenesis of Corpus Callosum; Antidepressive Agents; Antipsychotic Agents; Cognition Disorders | 2006 |
A model of anticholinergic activity of atypical antipsychotic medications.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Binding Sites; Clozapine; Cognition Diso | 2006 |
[Neurotoxicity related to lithium-risperidon combination treatment in a patient with schizoaffective disorder].
Topics: Antimanic Agents; Antipsychotic Agents; Cognition Disorders; Drug Interactions; Drug Therapy, Combin | 2007 |
[Psychiatric illness associated with amphetamines and other stimulants].
Topics: Adult; Amnesia; Amphetamines; Central Nervous System Stimulants; Cognition Disorders; Designer Drugs | 2000 |
Reversal of PCP-induced learning and memory deficits in the Morris' water maze by sertindole and other antipsychotics.
Topics: Analysis of Variance; Animals; Antipsychotic Agents; Behavior, Animal; Clozapine; Cognition Disorder | 2007 |
Cognitive-disruptive effects of the psychotomimetic phencyclidine and attenuation by atypical antipsychotic medications in rats.
Topics: Animals; Antipsychotic Agents; Attention; Benzodiazepines; Clozapine; Cognition Disorders; Dibenzoth | 2007 |
The relationship between symptomatic remission and neuropsychological improvement in schizophrenia patients switched to treatment with ziprasidone.
Topics: Adolescent; Adult; Antipsychotic Agents; Benzodiazepines; Cognition Disorders; Humans; Middle Aged; | 2007 |
Disruption of the neurokinin-3 receptor (NK3) in mice leads to cognitive deficits.
Topics: Age Factors; Animals; Antipsychotic Agents; Avoidance Learning; Behavior, Animal; Clozapine; Cogniti | 2007 |
Schizophrenic patients treated with clozapine or olanzapine perform better on theory of mind tasks than those treated with risperidone or typical antipsychotic medications.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Brief Psychiatric Rating Scale; Clozapine; Cognition; | 2007 |
Impairment in error monitoring predicts poor executive function in schizophrenia patients.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Clozapine; Cognition Disorders; Diagn | 2007 |
Behavioral and psychological symptoms assessed with the BEHAVE-AD-FW are differentially associated with cognitive dysfunction in Alzheimer's disease.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Antipsychotic Agents; Behavioral Symptoms; Cognition Dis | 2007 |
Long-term administration of the low-dose risperidone in schizotaxia subjects.
Topics: Adolescent; Adult; Antipsychotic Agents; Cognition Disorders; Drug Administration Schedule; Eye Move | 2007 |
Parent-rated anxiety symptoms in children with pervasive developmental disorders: frequency and association with core autism symptoms and cognitive functioning.
Topics: Adolescent; Aggression; Antipsychotic Agents; Anxiety; Asperger Syndrome; Attention Deficit Disorder | 2008 |
Parent-rated anxiety symptoms in children with pervasive developmental disorders: frequency and association with core autism symptoms and cognitive functioning.
Topics: Adolescent; Aggression; Antipsychotic Agents; Anxiety; Asperger Syndrome; Attention Deficit Disorder | 2008 |
Parent-rated anxiety symptoms in children with pervasive developmental disorders: frequency and association with core autism symptoms and cognitive functioning.
Topics: Adolescent; Aggression; Antipsychotic Agents; Anxiety; Asperger Syndrome; Attention Deficit Disorder | 2008 |
Parent-rated anxiety symptoms in children with pervasive developmental disorders: frequency and association with core autism symptoms and cognitive functioning.
Topics: Adolescent; Aggression; Antipsychotic Agents; Anxiety; Asperger Syndrome; Attention Deficit Disorder | 2008 |
Parent-rated anxiety symptoms in children with pervasive developmental disorders: frequency and association with core autism symptoms and cognitive functioning.
Topics: Adolescent; Aggression; Antipsychotic Agents; Anxiety; Asperger Syndrome; Attention Deficit Disorder | 2008 |
Parent-rated anxiety symptoms in children with pervasive developmental disorders: frequency and association with core autism symptoms and cognitive functioning.
Topics: Adolescent; Aggression; Antipsychotic Agents; Anxiety; Asperger Syndrome; Attention Deficit Disorder | 2008 |
Parent-rated anxiety symptoms in children with pervasive developmental disorders: frequency and association with core autism symptoms and cognitive functioning.
Topics: Adolescent; Aggression; Antipsychotic Agents; Anxiety; Asperger Syndrome; Attention Deficit Disorder | 2008 |
Parent-rated anxiety symptoms in children with pervasive developmental disorders: frequency and association with core autism symptoms and cognitive functioning.
Topics: Adolescent; Aggression; Antipsychotic Agents; Anxiety; Asperger Syndrome; Attention Deficit Disorder | 2008 |
Parent-rated anxiety symptoms in children with pervasive developmental disorders: frequency and association with core autism symptoms and cognitive functioning.
Topics: Adolescent; Aggression; Antipsychotic Agents; Anxiety; Asperger Syndrome; Attention Deficit Disorder | 2008 |
Association of subjective cognitive dysfunction with akathisia in patients receiving stable doses of risperidone or haloperidol.
Topics: Adult; Akathisia, Drug-Induced; Analysis of Variance; Antipsychotic Agents; Cognition Disorders; Fem | 2007 |
Social cognition [corrected] and neurocognition: effects of risperidone, olanzapine, and haloperidol.
Topics: Ambulatory Care; Antipsychotic Agents; Benzodiazepines; Cognition; Cognition Disorders; Emotions; Fa | 2007 |
Oculomotor and neuropsychological effects of antipsychotic treatment for schizophrenia.
Topics: Adult; Antipsychotic Agents; Cognition; Cognition Disorders; Female; Humans; Male; Neuropsychologica | 2008 |
Protracted effects of chronic oral haloperidol and risperidone on nerve growth factor, cholinergic neurons, and spatial reference learning in rats.
Topics: Acetylcholine; Administration, Oral; Animals; Antipsychotic Agents; Basal Nucleus of Meynert; Brain; | 2007 |
Comparison of haloperidol, risperidone, sertindole, and modafinil to reverse an attentional set-shifting impairment following subchronic PCP administration in the rat--a back translational study.
Topics: Animals; Antipsychotic Agents; Attention; Benzhydryl Compounds; Central Nervous System Stimulants; C | 2009 |
Neuroleptic malignant syndrome and catatonia in a patient with dementia.
Topics: Aged; Anti-Anxiety Agents; Antipsychotic Agents; Benzodiazepines; Catatonia; Chlorpromazine; Choline | 2008 |
The effect of risperidone on cognition in patients with schizophrenia.
Topics: Adult; Antipsychotic Agents; Arousal; Attention; Cognition Disorders; Female; Follow-Up Studies; Hum | 1996 |
Exacerbation of hallucinogen-persisting perception disorder with risperidone.
Topics: Adult; Antipsychotic Agents; Cognition Disorders; Female; Hallucinogens; Humans; Lysergic Acid Dieth | 1997 |
Relation of serum anticholinergicity to cognitive status in schizophrenia patients taking clozapine or risperidone.
Topics: Adult; Cholinergic Antagonists; Clozapine; Cognition Disorders; Female; Humans; Male; Middle Aged; M | 1998 |
Extrapyramidal side effects in a patient treated with risperidone plus donepezil.
Topics: Aged; Alzheimer Disease; Antipsychotic Agents; Basal Ganglia Diseases; Cholinesterase Inhibitors; Co | 1998 |
Psychiatric and neuropsychological abnormalities in Huntington's disease: a case study.
Topics: Antipsychotic Agents; Cognition Disorders; Female; Humans; Huntington Disease; Middle Aged; Psychoti | 1998 |
[Cognitive dysfunction in schizophrenia--new therapeutic possibilities. 11th ECNP. 31 October-4 November 1998, Paris].
Topics: Antipsychotic Agents; Cognition Disorders; Humans; Risperidone; Schizophrenia | 1998 |
[Neuro-cognition and schizophrenia. 11th World Congress for Psychiatry. Hamburg, 8 August 1999].
Topics: Antipsychotic Agents; Cognition Disorders; Haloperidol; Humans; Risperidone; Schizophrenia | 1999 |
Discriminant cognitive factors in responder and non-responder patients with schizophrenia.
Topics: Adult; Antipsychotic Agents; Attention; Clozapine; Cognition Disorders; Dibenzothiazepines; Female; | 1999 |
Normal P50 suppression in schizophrenia patients treated with atypical antipsychotic medications.
Topics: Acoustic Stimulation; Adult; Antipsychotic Agents; Auditory Perception; Benzodiazepines; Clozapine; | 2000 |
Case of pick's central lobar atrophy with apparent stabilization of cognitive decline after treatment with risperidone.
Topics: Adult; Antipsychotic Agents; Atrophy; Brain; Cognition Disorders; Female; Humans; Magnetic Resonance | 2000 |
Atypical antipsychotics and cognition in schizophrenia.
Topics: Antipsychotic Agents; Benzodiazepines; Cognition; Cognition Disorders; Dose-Response Relationship, D | 2002 |
Improvement of cognitive dysfunction after treatment with second-generation antipsychotics.
Topics: Antipsychotic Agents; Cognition; Cognition Disorders; Dose-Response Relationship, Drug; Drug Adminis | 2002 |